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ing tissue(s) and areas surrounding, such as with bone tissue. 
The two layers degrade at separate rates, thereby providing 
sustained mechanical support and tailored drug delivery. 
20 Claims, 19 Drawing Sheets 
U.S. Patent Feb.20,2018 Sheet 1 of 19 
FIGURE 1 
.... ·, Mold i!iiliiii CS Sluny ffirn CS Core ffirn CS S!x,!I 
US 9,895,354 B2 
2mm 
U.S. Patent Feb.20,2018 Sheet 2 of 19 US 9,895,354 B2 
FIGURE 2 
320 40 
ci,280 35 -;fl. 
::t. -0 
i 240 
(!) 
·:;. 30 
"' Cl 
"' ci 
11200 25 0:: 
0:: 
J 
Cl 
Cl> :::, 
2 160 j 20 0 
c 0 
o 120 15 
·=]=· Cl 
§
0 80 10 (!) 
� f � 
-:1: 
40 
·+
5 
0 0 
0 50 100 150 200 250 300 350 400 
Time, minutes 
U.S. Patent Feb.20,2018 Sheet 3 of 19 US 9,895,354 B2 
FIGURE 3 
U.S. Patent Feb.20,2018 Sheet 4 of 19 US 9,895,354 B2 
FIGURE 4 
11�'c 
* 
10% 
9% 
!---------------------------1 
,.e 
Q .. 8o/n 
§ 7%
� 6% 
;g 5% 
� 4%: 
� 30' 
a. 
,o 
2% 
1%, 
0% 
NL BSBC 1-BSBC 10-·BSBC 
U.S. Patent 
100°/.o ,,. 
90% 
80% 
,fl 
10% 
0 
Feb.20,2018 
4 8 
Sheet 5 of 19 
FIGURE 5 
12 1fi 20 
Time, Days 
+BSBG 
. .,,.1%-BSBC 
., 10%-BSBG 
24 28 
US 9,895,354 B2 
32 
U.S. Patent 
A. 
B. 
900 
o:i 
� 800 
�· 700 
:i 
"g 600 
::!: 
o 500
i
&j 400 
-� 300
., 
., 
e 200Q. 
� 100 
(,) 
0 
Feb.20,2018 Sheet 6 of 19 US 9,895,354 B2 
FIGURE 6 
U.S. Patent 
A. 
B. 
c. 
Feb.20,2018 Sheet 7 of 19 
1 . s ��::��sssr:����������������
1_6 . -
.:,:,·SSBC 
.. , .. BSSC 
a, 1.4 . , .. ssac + sssc 
13, 12 
j i.0 ·
� 0,1:J 
� 
� 0.6 
i.n 0.4 
0.2 
FIGURE 7 
) .. · .. ····· 
0.0 b. ��,;;;;;:;:;:;:;::==;:=:::::;.:.:.:�::==:;==:...-.,---,J 
0 
1.8
1
1.6 i 
I 
� :·: j g '·- I 
] I 
£ 1.0 i 
i: I � 0.8 i 
� I> O.i.l i
4 
+·BSSC
·«-·SSBC
,;, sssc
8 
.. ,, .. 8SSC+SS8C 
·;2 16 20 24 
Time, Days 
28 32 
.,>:
.,,,' ,· . � ;-'/ -1··· 
36 
-: 
.. •': 
.---�······· ...... �
� I 0.41 >-1' _ .. ·· � 
�:� Lc<::r:: ... �--------�----------�----------;··----- ---�-- -- --- --:· ······ -�-�:·········-�-0 4 8 12 16 20 24 28 32 36 
Time, Days 
3.5 +·f:lSSG 
3.0 
0 
.. »·SSBC 
,;,, sssc 
--•,.BSSC<·SSBC 
4 8 12 16 20 
Time, Days 
24 28 32 
US 9,895,354 B2 
U.S. Patent Feb.20,2018 
10 20 
Sheet 8 of 19 
FIGURE 8 
30 40 
Time, Days 
50 
US 9,895,354 B2 
60 70 
U.S. Patent Feb.20,2018 Sheet 9 of 19 US 9,895,354 B2 
FIGURE 9 
120 
110 
100 
# 90 
80 
70 
,:) 60 
.!::! 50 
40 
30 
20 
--01% PLGA (Metro.) 
-�1% SSBC
10 
·.,:,-1% BSSC
4 8 12 16 20 24 28 32 
A. Time, Days 
120 
110 
100 
,!:. 90 
<ii 
80 
70 
,:) 60 
.!":! 50 
40 
30 
20 +· 1 O'Y., PLGA {Metro.)
-w-10% SSBC
10 
·,:,:·10% BSSC
4 8 12 16 20 24 28 32 
8. Time, Days 
U.S. Patent Feb.20,2018 Sheet 10 of 19 US 9,895,354 B2 
FIGURE 10 
·. : .tnje¢t($-�heu.J
;,·,·=·=·=·=·=·=,·=·=:
:,:,:
Ill __ ,�-- r _____ " -�
!IIIIf It 1 •••. 1',,,1,,,,1
,,,,1,,,,1
,,,,1,,,,1
,,,,1,,,,1
,,,,1,,,,1
,,,,1,,,,1
,,,,1,,,,1
,,,,1,,,,1
,,,,1,,,,1
,,,,1,,,, .. ·1· ••• :·••.. :· ••. :·••. :· ••• :•••. :· ••,,.:',. :
•. I IIII (i iiiif ',,·,,.=,,·,,.=,,·,,.=,,·,,.=,,·,,.=,,·,,.=,,·,,.=,,·,,.=,,·,,.=,,·,,.':, ·• •. •••. ••• ••• • •• ••• ·,,.· • ••• ·=,,.'=,,·=,,.'=,,·=,,.'=,,·=,,.'=,,·=,,.'=,,·=,,.'=,,·=,,.'=,,·=,,.'=,,·=,,.'=,,·=,,.'=,, .. ........ ., ,,,., .. ;,;,;,;,;,;,;,;,;,;,: •. ,., .  ; •. ; . ,.,·,··====··=···=···=;:;;,,,·.· ·,,.f<'.= '=""''%·, •••••.Jl!l!l!l!l!l!l!!!I 
U.S. Patent 
B, 
Feb.20,2018 Sheet 11 of 19 
FIGURE 11 
32 
Timi:i, Days 
40 
DCPD·She!I, (§.Core 
32 
Time, Days 
40 
US 9,895,354 B2 
6(1 
U.S. Patent Feb.20,2018 Sheet 12 of 19 
1800 
1600 
1400 � 
31200 
= � 1000 
co: 
800 ,.,, 
.§ 600
rJ). 
400 
200 
0 
1800 
1600 
1400 
O£ 1200::. 
";;; 1000 
E 800
,.,, 
co: 
e 600 
en 400 
200 
0 
FIGURE 12 
A 
4 8 12 16 20 24 28 
Time (Days) 
B 
0 .-.c-������������� 
0 20 @ W W  1001201@1W1W 
Time (Days) 
US 9,895,354 B2 
U.S. Patent 
5000 
4500 
4000 
� 
3500 
3000 
.... 
2500 
"' 
2000 
E 
1500 
1000 
500 
0 
0 20 
Feb.20,2018 Sheet 13 of 19 
FIGURE 13 
�CP-1 --..-cP-2 --•--CP-4.8 
40 60 80 100 120 
Time (Days} 
US 9,895,354 B2 
140 160 180 
U.S. Patent 
1400 
1200 
_ 1000 
c 800 
.::; 
t: 
� 
E 
iii 
600 
400 
0 
Feb.20,2018 Sheet 14 of 19 
FIGURE 14 
�CS/CPs --+-- CPs/CS --e- CPs/CSs 
20 40 60 
Time (Days) 
80 
US 9,895,354 B2 
-II- CSs/CPs 
100 120 
U.S. Patent 
1400 ·
1
1200 ·:
1000 -� 
&800 .. j 
2 
Feb.20,2018 
;,�u 
Sheet 15 of 19 US 9,895,354 B2 
FIGURE 15 
• Ee CJcrult ,· 20 
CS CS-1 CP CP-1 CP-2 CP-4.8 CS/CP CP/CS 
U.S. Patent 
100% 
95% 
Feb.20,2018 Sheet 16 of 19 US 9,895,354 B2 
FIGURE 16 
0 16 32 48 64 80 96 112 
Time (Days) 
U.S. Patent Feb.20,2018 Sheet 17 of 19 US 9,895,354 B2 
FIGURE 17 
U.S. Patent Feb.20,2018 Sheet 18 of 19 US 9,895,354 B2 
12. 
lO 
"' 
g 
� 
6 
v 
4 :::, 
2. 
0 
FIGURE 18 
IJ 11 lJ 
OCPO--sjngl<! l;,�r OC!'O--sh<!!l, CS·rorn OCPO--ronl:, CS·sheH CS�ir,gle la,....- Traba,a;l;,, bone 
{miimll!:l!e} 
500 
./100 
300 � 
WO :{ 
100 
0 
U.S. Patent Feb.20,2018 Sheet 19 of 19 US 9,895,354 B2 
FIGURE 19 
100 
US 9,895,354 B2 
1 
BILAYERED CALCIUM SULFATE/CALCIUM 
PHOSPHATE SPACE-MAKING COMPOSITES 
WITH MULTIPLE DRUG DELIVERY 
CAPABILITIES 
RELATED APPLICATIONS 
This application claims priority to U.S. Provisional Patent 
Application 61/975,133, filed 4 Apr. 2014, which is hereby 
incorporated by reference in its entirety. 
GOVERNMENT INTEREST 
This invention was made with Govermnent support from 
grants NIH DE019645 and EPS-0814194 awarded by the 
National Institutes for Health and the National Science 
Foundation, respectively. The Govermnent may have certain 
rights in the invention. 
TECHNICAL FIELD 
2 
ever, these procedures also may require a second surgery to 
remove non-biodegradable barrier membranes, and bone 
grafting may cause morbidity in the donor site (Chiapasco, 
M., Zaniboni, M., Rimondini, L., 2007. Autogenous onlay 
bone grafts vs. alveolar distraction osteogenesis for the 
correction of vertically deficient edentulous ridges: a 2-4-
year prospective study on humans. Clinical Oral Implants 
Research 18, 432-440; Guarnieri, R., Grassi, R., Ripari, M., 
Pecora, G., 2006. Maxillary sinus augmentation using 
10 
granular calcium sulfate (surgiplaster sinus): radiographic 
and histologic study at 2 years. International Journal of 
Periodontics and Restorative Dentistry 26, 79-85; Triplett, 
R. G., Schow, S. R., 1996. Autologous bone grafts and
endosseous implants: Complementary techniques. Journal
of Oral and Maxillofacial Surgery 54, 486-494). A strong
15 biocompatible material that can effectively promote osteo­
genesis while acting as an effective barrier and/or support 
thus preventing disruptive tissue from infiltrating would be 
an effective alternative for the procedure. Release of bioac­
tive agents and/or the combination of materials to create a 
20 stable augmenting platform could be a suitable substitute to 
the existing standard autografts. 
The present invention relates generally to methods of 
improving bone regeneration or augmentation through the 
introduction of bilayered composites comprising an outer 
shell and an inner core, wherein the two layers degrade or 25 
erode at different rates in situ, thereby allowing for mechani-
SUMMARY OF THE INVENTION 
The present invention provides for a bilayered composite 
to provide mechanical support, as well as to provide local­
ized drug delivery comprising an outer shell layer and an 
inner core layer, wherein one layer degrades in situ within a 
subject at a rate faster than the other layer. The outer shell 
layer may degrade faster than the inner core layer, or the 
cal support to tissues while improving administration of 
therapeutic compounds dispersed within one or both of the 
layers. 
BACKGROUND 
30 inner core layer may degrade faster than the outer shell layer. 
One layer layer may comprise a material selected from the 
group consisting of dicalcium phosphate dihydrate (DCPD), 
hydroxyapatite, calcium-deficient hydroxyapatite, carbon­
ate-substituted hydroxyapatite, and calcium polyphosphate. 
A traumatic event to the bone, such as that seen with 
surgical procedures, can require many varied therapies to 
improve recovery and healing. Often it is contemplated that 
providing mechanical support in conjunction with delivering 
therapeutic compounds at the surgical site can aid in improv­
ing the recovery process. However, the differing rates of 
absorption and metabolism can make effective delivery very 
complicated. The capacity to quickly regenerate or augment 
bone lost as a result of resorption and trauma is crucial to 
restoring proper function and aesthetics. In addition to 
existing bone grafts, both autologous and allogeneic, a 
variety of bone graft substitutes are being developed (Ilan D. 
I, Ladd A. L. (2004) Bone graft substitutes, Operative 
Techniques in Plastic and Reconstructive Surgery, 9.4, 151-
160). 
35 The other layer may comprise a material selected from the 
group consisting of calcium sulfate (CS), (3-tricalcium 
phosphate, amorphous calcium phosphate, monetite, and 
tetracalcium phosphate. 
In certain embodiments, one layer comprises calcium 
40 sulfate and the other layer comprises calcium phosphate. 
The calcium phosphate may be dicalcium phosphate dehy­
drate. 
In certain embodiments, at least one layer further may 
comprise a pharmaceutical agent selected from the group 
45 consisting of: simvastatin, lovastatin, rosuvastatin, SVAK-
12, bone morphogenetic proteins, parathyroid hormone 
(1-34), metronidazole, doxycycline, vancomycin, gentamy­
cin, ciprofloxacin, ketoprofen, celecoxib, diclofenac, 
meloxicam or combinations thereof. In other embodiments, 
A common procedure to treat osseous defects is bone 
grafting which takes tissue from a donor site that is trans­
planted to a defective region. For instance, in dentistry, this 
procedure is used in conjugation with guided bone regen­
eration (GBR) for regions in the mandible where bone has 
been resorbed or deformed due to the loss of teeth, peri­
odontal disease or trauma to the jaw. GBR is a procedure 
which implants a barrier membrane over donated bone 
material to prevent infiltration of epithelium and connective 
tissue which may disrupt bone formation (Simian, M., 
Fontana, F., Rasperini, G., Maiorana, C., 2007. Vertical ridge 
augmentation by expanded-polytetrafluoroethylene mem­
brane and a combination of intraoral autogenous bonegraft 
and deproteinized anorganic bovine bone (Bio Oss ). Clinical 
Oral Implants Research 18, 620-629). Depending on the 
barrier material, there can be a tendency to collapse, which 
will require bone grafting to provide a biodegradable and 
stable support structure as osteogenesis occurs (Hitti, R. A., 65 
Kerns, D. G., 2011. Guided bone regeneration in the oral 
cavity: a review. Open Pathology Journal 5, 33-45). How-
50 both layers further comprise a pharmaceutical agent. 
Optionally, the pharmaceutical agent may be preloaded in a 
degradable matrix or a hydrogel. 
The present invention also provides methods of providing 
tissue support to a subject in need thereof, comprising 
55 administering the bilayered composite to tissue of a subject. 
The tissue may be osseous tissue. The subject may be an 
animal, such as a vertebrate. The subject may be a fish, 
mammal, amphibian, reptile or bird. The subject may be a 
human. The methods may further comprise preloading at 
60 least one layer with a pharmaceutical agent. Optionally, the 
pharmaceutical agent is in a degradable matrix or hydrogel 
within the layer. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 shows a schematic depicting the process of form­
ing a bilayered CS composite. From left to right: core 
US 9,895,354 B2 
3 
formation; insertion of core into shell mold; final composite 
showing core encased within a CS shell. Images are to scale. 
FIG. 2 shows cumulative release of metronidazole from 
150-250 µm PLGA particles. Data are mean±standard devia­
tion (n=3). 
FIG. 3 shows representative microCT images of 
CS/PLGA composites: raw X-ray slices and cross-sections 
of 3D reconstructions. Closed arrows mark bubbles, and 
open arrows with circles indicate PLGA particles. Scale bars 
denote 1 mm. 
FIG. 4 shows volume percentage of voids/particles in 
CS/PLGA composites determined by microCT. Data are 
mean±standard deviation (n=5). Symbols (*) indicates sig­
nificant differences (p<0.001). 
FIG. 5 shows mass loss profiles for bilayered blank CS 
and composites with 1 and 10 wt % PLGA loaded into the 
shells. Data are mean±standard deviation (n=3). 
FIG. 6 shows mechanical properties of CS/PLGA com­
posites with directly loaded simvastatin: A) ultimate com­
pressive strength and B) compressive modulus. Data are 
mean±standard deviation (n=5). Symbols indicate signifi­
cant differences: p<0.001 (*), p<0.01 (#), and p<0.05 (ll). 
FIG. 7 shows cumulative release of simvastatin from 
bilayered samples having different shell to core volume 
ratios: (A) 85:15; (B) 75:25; and (C) 50:50. Data are 
mean±standard deviation (n=5). 
FIG. 8 shows cumulative release of simvastatin from 
bilayered samples incubated below sink conditions. The 
samples tested had a 50:50 shell to core volume ratio. Data 
are mean±standard deviation (n=5). 
FIG. 9 shows cumulative release of simvastatin and 
metronidazole from bilayered composites. Normalized pro­
files of directly loaded simvastatin and metronidazole loaded 
into PLGA particles released from composites with (A) 1 wt 
% and (B) 10 wt% PLGA particles loaded in shells. Data are 
mean±standard deviation (n=5). 
FIG. 10 shows a schematic depicting the packing of the 
DCPM core and injection of CS shell around the core. The 
bottom, red portion, of each mold is removable allowing for 
the punching out of the samples. Final adjustments are made 
to the exposed portion of the DCPM core by sanding it flush 
to the shell. 
FIG. 11 shows microCT reconstructions of microarchi­
tectural changes for A.) CS in shell, DCPD in Core samples, 
and B.) DCPD in Shell, CS in Core samples. 
FIG. 12 shows cumulative release of simvastatin from CS 
(top) and DCPD (bottom) samples at 1 wt % Data is 
mean±standard error of mean (SEM) (n=5). 
FIG. 13 shows cumulative releases of simvastatin from 
DCPD samples at 1 wt %, 2 wt %, and 4.8 wt %. Data is 
mean±SEM (n= 5). 
FIG. 14 shows cumulative releases of simvastatin from 
CSs/CPs, CPs/CSs, CPs/CS, and CS/CPs. Simvastatin load­
ings are denoted by the lowercase s. 2 wt % is loaded in 
DCPD layers and 1 wt % in CS layer. 
FIG. 15 shows compressive elastic modulus and ultimate 
compressive stress of non-layered and bilayered CS and 
DCPD implants at different simvastatin loadings in non­
layered samples. Data is mean±SEM (n=8-10). 
FIG. 16 shows percentage of initial mass remaining from 
DCPD samples at every 8 days over a period of 128 days. 
Data are mean±SEM (n= 3). 
FIG. 17 shows microCT cross-sections of DCPD samples 
during erosion in PBS. 
FIG. 18 shows compression testing results displaying the 
ultimate compressive stress (UCS, left) and the compressive 
elastic modulus (M, right). 
4 
FIG. 19 shows representative mass loss (top) and pH 
(bottom) during destructive degradation testing. 
DESCRIPTION 
The present invention provides for a bilayered composite 
to assist in bone augmentation, such as rebuilding and 
healing at the site of injury or surgical repair to bone or 
osseous tissue, such as that seen with dental or orthopedic 
10 surgeries. The bilayered composites of the present invention 
comprise an outer shell layer and an inner core layer. Either 
layer may be loaded or incorporated with a therapeutic 
compound, either both with the same or with different 
compounds. The two layers are comprised of biomaterials 
15 that degrade or erode at different rates once placed in situ 
within a subject. The bilayered composites, in addition to 
delivering therapeutic compounds, further provide structural 
protection, such as a "tenting" of surrounding soft tissue to 
create a regeneration chamber for bone, thus removing need 
20 for harvesting tissue for grafts. The following describe 
background of the present invention: Oreliana, B. R., 
Thomas, M. V., Hilt, J. Z., and Puleo, D. A. (2013). 
Bioerodible calcium sulfate hemihydrate/poly(�-amino 
ester) hydrogel composites, J. Mech. Behav. Biomed. Mater. 
25 26:43-53; Oreliana, B. R. and Puleo, D. A. (2014). Tailored 
sequential drug release from bilayered calcium sulfate com­
posites, Mater Sci Eng C Mater Biol Appl. 43:243-52; 
Oreliana, B. R., Hilt, J. Z., and Puleo, D. A. (2015). Drug 
release from calcium sulfate-based composites, J. Biomed 
30 Mater Res. Part B 2015 103(1 ): 135-42; Oreliana, B., Hawk­
ins, A. M., Thomas, M. V., Hilt, J. Z., and Puleo, D. A. 
(2010). Calcium sulfate/hydro gel space-making composites 
for bone augmentation. Presented at the 2010 Annual Meet­
ing of the Society For Biomaterials, April 21-24, Seattle, 
35 Wash.; Oreliana, B. R, Thomas, M. V., Hilt, J. Z., and Puleo, 
D. A. (2011). Drug delivery from calcium sulfate/hydrogel
space-making composites. Presented at the 2011 Annual
Meeting of the Society For Biomaterials, April 13-16,
Orlando, Fla.; Oreliana, B. R., Thomas, M. V., Hilt, J. Z., and
40 Puleo, D. A. (2012). Drug delivery from space-Making 
calcium sulfate/poly(�-amino ester) hydrogel composites. 
Presented at the AADR Annual Meeting, March 21-24, 
Tampa, Fla.; Oreliana, B. R., Thomas, M. V., Hilt, J. Z., and 
Puleo, D. A. (2013). Bilayered calcium sulfate space-making 
45 composites with multiple drug delivery capabilities. Pre­
sented at the 2013 Annual Meeting of the Society For 
Biomaterials, April 10-13, Boston, Mass.; Oreliana, B. R., 
McQuinn, M. W., and Puleo, D. A. (2014). Tailored prop­
erties of bilayered calcium sulfate and calcium phosphate 
50 bone graft substitutes. Presented at the 2014 Annual Meeting 
of the Society For Biomaterials, April 16-19, Denver, Colo.; 
McQuinn, M. W., Oreliana, B. R., and Puleo, D. A. (2014). 
Bilayered calcium phosphate/calcium sulfate bone graft 
substitutes. Presented at the 2014 Annual Meeting of the 
55 American Association of Oral and Maxillofacial Surgeons, 
September 8-13, Honolulu, Hi.; Gu, Y., Oreliana, B. R., and 
Puleo, D. A. (2015). Simvastatin-releasing calcium sulfate 
and calcium phosphate bioceramics. Presented at the 2015 
Annual Meeting of the Society For Biomaterials, April 
60 15-18, Charlotte, N.C. 
Because space maintenance and stimulation of osteogen­
esis is important for many dental, craniofacial, and ortho­
pedic procedures, the implanted bilayered composites of the 
present invention can be useful in many applications requir-
65 ing bone grafting/bone graft substitutes. These include ridge 
augmentation for placement of dental implants, ridge pres­
ervation following tooth extraction, reconstruction of cavi-
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tary bone defects, regeneration in segmental bone loss, and 
enhancement of interbody spinal fusion. 
The bilayered composite system of the present invention 
6 
demonstrate that changing the shell to core volume ratio 
dictates the duration of drug release from each layer. 
By introducing a tunable layered geometry capable of 
releasing multiple drugs, the bilayered composites of the 
present invention provide bone graft substitutes that can be 
tailored in order to help streamline multiple steps needed to 
regenerate tissue in infected defects. As also demonstrated in 
the working examples, when loaded together in the shell or 
in separate layers, sequential release of two therapeutic 
is amenable to formulation with varied biomaterials. 
According to the present invention, one of the selected 
biomaterials should be proceed at a slower eroding/degrad­
ing/dissolving rate than the other. Those skilled in the art 
will appreciate that different benefits may be achieved when 
the order of the layers is varied. For example, placement of 
the more rapid degrading biomaterial as the outer shell, 
allows for faster rates of therapeutic delivery of compounds 
contained in the outer layer, as well as a faster access to the 
slower degrading core and any therapeutic compounds con­
tained therein. Conversely, placement of the slower degrad­
ing biomaterial as the outer core allows for reduced rates of 
release of therapeutic compounds from this layer, as well as 
a prolonged time of access to the core, as well as any 
therapeutics contained therein. 
10 agents is achieved. Qualitative assessment of the morphol­
ogy of bilayered composites showed good distribution of 
therapeutic carrying degradable matrix, such as PLGA, 
microparticles (without or loaded with a therapeutic agent) 
embedded in at least one layer of the bilayer composite 
15 between 1 and 10 wt %. Those skilled in the art will 
As set forth in the working examples, dicalcium phos­
phate dihydrate (DCPD or brushite, a form of calcium 20 
phosphate, CP) provides for a slower degrading biomaterial 
and calcium sulfate (CS) is a faster degrading biomaterial. 
Other possible biomaterials include, but are not limited, to 
the following: 
Slower degrading: hydroxyapatite, calcium-deficient 25 
hydroxyapatite, carbonate-substituted hydroxyapatite, 
and calcium polyphosphate 
Faster degrading: �-tricalcium phosphate, amorphous cal­
cium phosphate, monetite, and tetracalcium phosphate 
Further, as set forth in the working examples, metronida- 30 
zole and simvastatin can be used as antimicrobial and 
osteogenic agents that are impregnated or deposited into the 
layers of the bilayered composite. Those skilled in the art 
will appreciate that any therapeutic compound can be con­
sidered, taking into account the respective solvency once in 35 
situ, as well as how a selected agent may align/interact with 
appreciate that higher content can also be utilized, particu­
larly in instances where the mechanical support is of reduced 
concern, such as with non-load bearing sites. Although the 
embedded particles were distributed throughout the matrix, 
they did not appear to be interconnected, which otherwise 
would have allowed for fluid to seep into the composite. 
During erosion, closed pockets with drug-loaded particles 
near the surface were exposed, thereby releasing the poly­
mer particles. The introduction of a bilayered geometry 
affected properties compared to solid samples, with a reduc­
tion in the strength and elastic modulus. The loading of 
therapeutic compounds directly into the shell, core, or both 
layers did not significantly affect the strength of the bilay­
ered composites. The layered geometry used from the 
examples described herein demonstrate a unique platform 
for achieving customizable sequential release of therapeutic 
agents. Loading of drug carrying microparticles into the 
matrix allows for further tailoring of drug release. 
The release of therapeutic compounds and the carriers 
thereof can be tailored depending on the layer in which the 
therapeutics are loaded. For example, as set forth in the 
examples, simvastatin delivery can be tailored depending on 
whether it was the shell only, core only, or both. 
To further adjust the duration or even the delay of drug 
a potential biomaterial that formulates the particular layer. 
Particular classes of therapeutic compound are worth con­
sidering given the purpose of assisting in bone augmenta­
tion. These include, but are not limited, to the following: 
Antimicrobial agents-such as: metronidazole, doxycy­
cline, vancomycin, gentamycin, and ciprofloxacin 
Osteogenic agents-such as: simvastatin, lovastatin, rosu­
vastatin, SVAK-12, bone morphogenetic proteins, and 
parathyroid hormone (1-34) 
40 release from either the shell or core, the shell to core volume 
ratio can be altered. For example, the findings for samples 
with metronidazole within PLGA particles and with simv­
astatin directly loaded into a shell demonstrated sequential 
release: polymeric particles loaded with metronidazole and 
Anti-inflammatory agents-such as: ketoprofen, cele-
coxib, diclofenac, and meloxicam 
Those skilled in the art will appreciate that the therapeutic 
agents incorporated within each layer may be further incased 
45 embedded into the shell were exposed as the shell experi­
enced surface erosion, and a sustained release of the drug 
occurred as the PLGA particles subsequently degraded. To 
further enhance the process of fighting infection and then 
in an additional biomaterial, such as a hydrogel or degrad- 50 
able matrix, to further affect the release. Examples include, 
but are not limited to poly (lactic-co-glycolic) acid (PLGA), 
poly(�-amino ester) (PBAE), cellulose acetate phthalate and 
phronic F-127. 
The tailorable bilayered composites may function as bone 55 
graft substitutes or part thereof and provide the ability once 
in situ to sequentially release multiple therapeutic agents. As 
set forth in the working examples herein, microcomputed 
tomography (MicroCT) images exemplify the overall lay­
ered geometry as well as uniform distribution of particles 60 
within the bilayered composites. 
Those skilled in the art will appreciate that the portion 
each layer contributes to the overall composition can alter 
the activity and function when in situ. For example, the 
working examples provide a demonstration of release of 65 
simvastatin within a CS layer. The data generated from 
sustained release of simvastatin directly loaded into CS 
regenerating lost tissue, release of an anti-bacterial agent 
from the graft starting at the time of implantation can be 
beneficial to help reduce the overall healing time. The 
release of a therapeutic, as seen with simvastatin in the 
examples, is, therefore, governed by the surface erosion 
characteristics, which have demonstrated to be linear, allow­
ing for a near constant rate of release of simvastatin. The 
apparent differences in release kinetics between the two 
drugs and their means of loading allowed for enough sepa­
ration for all the metronidazole to be released approximately 
4 days sooner than simvastatin. Conversely, when simvas­
tatin was loaded into only the core and PLGA particles 
loaded with metronidazole remained in the shell, there was 
a much greater lapse in time for a fully separated sequential 
release to occur. Instances such as this can mimic the clinical 
sequence of events for treating infection and subsequently 
restoring lost or damaged tissue. When metronidazole and 
simvastatin were loaded together in the shell or in separate 
layers, temporal separation of the two drugs was achieved. 
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The ability of the present invention to provide tailored 
release of therapeutic agents as well as a sequential release 
of different drugs, may be utilized in many scenarios, such 
as a bone graft substitute for treating infected bony defects, 
e.g., periodontal pockets. Changing the shell to core volume
ratio dictates the duration of drug release from each layer.
With the bilayered composites of the present invention, 
the ratio of shell to core may vary according to the desired 
outcome. The percent of shell to the total composite may be 
8 
and/or the combination of materials to create a stable 
augmenting platform suitable as a substitute to the existing 
standard autografts. 
The bilayered composites of the present invention provide 
for a composite that retains the benefits from the properties 
of the biomaterial of each layer, with the addition of the 
other layer overcoming any deficiencies. For example, as set 
forth in the working examples, release of simvastatin 
5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 10 
85, 90, or 95%. Conversely, the percent of the core to the 
total composite may be 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 
directly loaded into a "fast" degrading material implant, 
calcium sulfate (CS), and a "slow" degrading material 
implant, calcium phosphate (CP) (such as DCPD), demon-
strated release rates of approximately 59 and 7 µg/day for CS 
and CP, respectively. Mechanical testing showed CP to have 
significantly (p<0.05) greater compressive strength (FIG. 15 
and modulus than did CS. There were no significant differ­
ences between CP of different simvastatin loadings. CP 
55, 6� 65, 7� 75, 8� 85, 9� or 95%. 
The therapeutic compounds loaded into the layers of the 
composite may comprise any known pharmacologic agent or 15 
any combination thereof. Therapeutic agents may be 
encased or protected prior to loading within either layer of 
the shell, such as with degradable matrices like PLGA. 
Examples of therapeutic compounds that may be beneficial 
eroded much more slowly than CS when incubated in 
phosphate-buffered saline; CS was gone within 28 days, 
while CP lasted more than 180 days. Loading did not affect 
erosion. MicroCT scans showed that CP developed a porous 
internal structure as it eroded (FIG. 17). However, in com-
to osseous tissue, such as bone and/or dental areas, receiving 20 
the bilayered composites include: proteins/growth factors, 
such as bone morphogenetic proteins (BMPs) 2, 4, 7, and 9; 
statin drugs, such as simvastatin, lovastatin, fluvastatin, and 
mevastatin; antibiotics, such as metronidazole, doxycycline, 
gentamicin, and vancomycin; and anti-inflammatory agents, 25 
such as ketoprofen, naproxen, and celecoxib. 
bining the slow dissolving properties of DCPD with CS in 
a bilayered composite, a 'middle ground' is established 
where sufficient scaffolding is maintained as CS dissolves 
and cell infiltration occurs in the slower dissolving DCPD. 
Release of simvastatin from CS samples occurred at a much 
With regard to oral surgeries, in testing the bilayered 
composites, it was noted that although the compressive 
properties decreased with the introduction of a layered 
geometry, the resulting strengths seen with faster degrading 30 
materials, such as calcium sulfate, in the bilayered compos­
ites remained either similar to or stronger than the strength 
higher rate than DCPD samples, as expected from CS's 
faster dissolution rate. Release rates were approximately 24 7 
and 29 µg/day for CS-1 and CP-1, respectively. Increasing 
the amount of simvastatin added to DCPD resulted in a 
loading-dependent increase in release rate (i.e., 45 and 105 
µg/day for 2 and 4.8 wt % simvastain loadings, respec­
tively). Mechanical testing showed DCPD to all have sig­
nificantly (p<0.05) greater ultimate compressive strength 
of trabecular bone in the mandible and the combination of 
the faster/slower degrading materials, such as calcium sul­
fate/calcium phosphate samples, were even stronger still. 
The present invention provides for bilayered composites 
in a variety of final shapes. Preformed scaffolds can be 
designed to allow fabrication of a variety of shapes. The 
bilayered geometry allows for sequential release of multiple 
drugs. Incorporated biomaterial of differing degradation 
rates, such as CS and DCPD, into separate layers allows for 
customizable erosion. For example, structures can exhibit 
fast initial erosion of a CS shell while maintaining the DCPD 
core and vice versa. Examples of microCT reconstructions 
of dissolution trends are seen in FIG. 8. 
The erosion pattern of the layered materials within the 
bilayered composites allows for erosion tuning and customi­
zable drug release that further assist in functioning as a bone 
graft substitute. Slower degrading biomaterials, such as 
DCPD, have demonstrated to be a more durable ceramic as 
compared to fast degrading materials, such as CS, lasting 
well over 180 days in release studies. For example, DCPD 
samples sustained much larger compressive forces and 
released at much slower yet steady rates in lower loadings. 
The bulk degradation property of CP may be beneficial for 
bone augmentation by allowing for cell infiltration and 
increasing surface area for growth. Bilayered composites are 
able to degrade and permit more space for bone growth than 
non-layered samples of slower degrading material, such as 
DCPD, while also maintaining a longer lasting support 
structure, unlike faster degrading materials like CS. 
Bilayered composites of the present invention can further 
act as 'tenting' barriers to prevent or hinder soft tissue 
infiltration, while allowing a well-tailored delivery of a 
variety of treatment specific drugs directly loaded in the 
material of a particular layer and/or embedded in biodegrad­
able hydrogel particles. The release of bioactive agents 
35 and compressive modulus than did CS (FIG. 15). Addition­
ally the strength and modulus of both bilayered samples 
were significantly lower (p<0.01) than that of DCPD blanks. 
The compressive mechanical properties of both bilayered 
samples were comparable (p>0.05) to that of CS blanks. 
40 There was also no significant difference found between the 
compressive mechanical properties of CS/CP bilayering 
compared to CP/CS bilayering. MicroCT scans also showed 
qualitatively that DCPD developed a porous internal struc­
ture as it eroded. 
45 According to the present invention, higher loadings 
should be preferred over lower loadings in order to achieve 
a higher average release rate, while lower loadings are 
preferred over higher loadings in order to achieve a steadier 
release rate. Due to rapid dissolution, faster degrading 
50 material as the shell layering has a higher release rate in the 
first weeks of its dissolution. Additionally, such samples 
result in greater mass loss since more surface area is 
exposed, leaving behind the slower degrading core. This is 
beneficial for providing longer-lasting scaffolding for 
55 implantations while also allowing room for sufficient bone 
growth as the outer shell layer dissolves. 
Degradation of the implants can be slowed by selecting a 
slower degrading material as an outer shell and selecting the 
faster degrading material to compromise the inner core. As 
60 described herein, with the slower degrading DCPD and 
faster degrading CS, DCPDs/CS and CS/DCPDs formula­
tions had a slower yet more linear release rate compared to 
other bilayered formulations. DCPD shells release at a 
higher rate by occupying more volume compared to DCPD 
65 cores. The formation of an empty core as slow degrading­
shell samples dissolve can also be beneficial for providing 
greater mechanical strength than a using a slow degrading 
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core while also allowing for bone growth to occur at the 
center of the shell. The quality for both fast and slow 
degrading materials to retain their mechanical properties at 
the loadings tested provides for more options in controlled 
drug release which is important for regions of bone defect 5 
where healing is slower and requires increased drug loadings 
to compensate. The mechanical properties observed in the 
examples were also found to be higher than those of trabe­
cular bone in the mandibles (96.2 MPa compressive modu­
lus; 3.9 MPa ultimate compressive strength) (Misch C E, Qu 10 
Z, Bidez M W. Mechanical properties of trabecular bone in 
the human mandible: Implications for dental implant treat­
ment planning and surgical placement. J Oral Maxi! Surg. 
1999; 57:700-6; McQuinn, M. (2014, September). Bilayered 
Calcium Phosphate/Calcium Sulfate Bone Graft Substitutes. 15 
Poster presented at the 96'h Annual Scientific Sessions & 
Exhibition, Honolulu, Hi.). Accordingly, while the bilayered 
composites may not be as stiff as non-layered samples, they 
can carry the same load before failure. A redeeming quality 
is that the inclusion of slower degrading materials allows for 20 
an adequate support structure in implantation sites much 
longer due to its slower dissolution. The structure of slower 
degrading materials, such as DCPD, allows for infiltration of 
cells such as osteoblasts as it degrades while osteogenic 
activities can promoted by the local release of a therapeutics 25 
(seen with simvastatin in the examples). MicroCT scans of 
such embodiments showed slight surface imperfections in 
DCPD samples even before degradation testing began. 
These surface imperfections were found to be as wide as 100 
µm in diameter which is sufficient to permit infiltration of 30 
osteoblasts (20-30 µm). The much slower degradation rate is 
also beneficial for maintaining a slow consistent release over 
a sustained period time as observed in the release study. 
These issues can be addressed by combining the two ceram-
ics using the bilayered composites, thereby providing a 35 
longer lasting support structure (e.g., DCPD) while also 
permitting sufficient bone growth to occur within the core as 
the faster degrading material ( e.g., CS) is dissolved. Further, 
after bone ingrowth has occurred within the core of the 
slower degrading shell, mechanical properties can expect to 40 
see a boost due to the presence of both bone and the shell. 
Additionally, cell infiltration and resorption can occur on 
both sides of the shell, thereby allowing for better integra­
tion of bone and effectively reducing the degradation time. 
Additionally, the osteogenic activity can be enhanced by the 45 
steady and predictable release of therapeutics ( e.g., simvas­
tatin) from the implanted composite, all without compro­
mising the initial mechanical strength of the commonly used 
biomaterial CS. 
10 
posite means that no additional surgery is required for 
removal, although it can be removed as needed. 
EXAMPLES 
Example 1 
Bilayered Calcium Sulfate Composites 
Metronidazole-Loaded PLGA Particles 
Poly(lactic-co-glycolic acid) (Durect Corp., Birmingham, 
Ala.; 50:50; inherent viscosity: 0.55-0.75 dL/g; carboxylate 
end group) particles loaded with metronidazole (Sigma­
Aldrich, St. Louis, Mo.) were created by film-casting and 
hand-grinding. Initially, 25 mg of metronidazole were com­
bined with 200 mg of PLGA and dissolved in 1 mL of 
dimethyl sulfoxide (DMSO; an FDA Q3C Class 3 solvent). 
The solution was poured into a circular Teflon mold, frozen 
quickly at -80° C., and lyophilized to remove the DMSO. 
The dried film was hand ground to obtain particle sizes 
between 150-250 µm. A small amount of CS was used to 
prevent the polymer from sticking during grinding. The 
particles were washed with ethanol to remove residual CS 
powder on the surface of the polymer. Ethanol was chosen 
for washing to prevent drug loss because the low solubility 
of metronidazole in this solvent. Washed particles were 
vacuum-filtered, rapidly air-dried, and stored at -20° C. until 
used. 
A short-term study of metronidazole-loaded micropar­
ticles was conducted to determine how much drug may be 
released during the setting phase of composite formation. 
For this purpose, 10 mg of washed PLGA particles were 
incubated at 37° C. in 1 mL of phosphate-buffered saline 
(PBS), pH 7.4. Supernatant was collected and replaced with 
fresh PBS every 15 min for the first hr, every 30 min for the 
2nd hr, every hr for the 3rd and 4th hr, and finally increased 
to every 2 hr for the 6'h and 8'h hr time points. Supernatants 
were filtered (0.45 µm) and the absorbance measured at 318 
nm. 
Bilayered Calcium Sulfate Composites 
Fabrication of the bilayered composites is illustrated in 
FIG. 1. The composites consisted of calcium sulfate hemi­
hydrate (Sigma-Aldrich) as the structural matrix. First, blank 
CS samples without layers were produced by combining 1 g 
of CS with 800 µL of deionized (DI) water. The slurry was 
injected into a mold having a diameter of 6.3 mm and a 
height of 12.6 mm. The loaded mold was placed in a 43° C. 
oven for 24 hr to allow for the CS to completely set. 
To begin formation of bilayered composites, cylindrical 
cores were produced in Teflon molds having a diameter of 
The present invention provides for methods of using the 
bilayered composites. The methods comprise administering 
to the osseous tissue of a subject the bilayered composites as 
described herein. The subject can be a vertebrate animal, 
such as a bird, reptile, amphibian, fish or mammal. The 
subject may be a human. The osseous tissue may comprise 
bone or periodontal tissue. The bilayered composite may be 
applied directly to the tissue, such as through implantation 
during surgery or may be applied less invasively, such as 
through injection. 
50 4.7 mm and a height of 10 mm. A small, 8 mm long metal 
peg with a 0.63 mm diameter was fitted precisely in the 
center of the mold, with about 2.5 mm of the peg embedded 
into the core. The pegs suspended and centered the cores for 
shell production later. To make blank CS cores, 800 µL of DI 
Once deposited, the bilayered composite remains in situ 
with the subject. As described herein, the bilayered com­
posite may release one or more pharmaceutical agents 
within the subject. Further, as also described herein, the 
bilayered composite provides structural support to the tissue, 
55 water was added to 1 g of CS powder and mixed thoroughly 
in 3 mL non-sterile syringes fitted with a 16 gauge blunt 
needle. The slurry was loaded into the custom-fabricated 
Teflon mold and placed in a 43° C. oven for 24 hr to set the 
CS. For cores loaded with simvastatin, the same process was 
60 used, however 20 mg of simvastatin (Haouri Pharma-Chem, 
Inc., Edison, N.J.) were mixed along with the CS and DI 
water. Pegs were removed from the cores when they were 
dried, and the cores were stored at room temperature with 
desiccant until used. 
as well as preventing or hindering surrounding soft tissue 65 
from migrating to the osseous tissue. As described herein, 
the degradable nature of both layers of the bilayered com-
To form the shell around the cores, another Teflon mold 
was created with cylindrical holes having the diameter of 6.3 
mm and a height of 12.6 mm. The base plate was fabricated 
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with 3.5 mm deep holes into which metal pegs were securely 
inserted. This depth allowed the cores to be positioned 
precisely in the center of the mold, thus allowing the shell 
12 
Composite Microarchitecture 
To monitor the distribution of PLGA particles within the 
CS shell matrix as well as the interface between shell and 
core, microcomputed tomography (microCT) was 
employed. Using a Scanco Medical µCT-40 scanner, speci­
mens were evaluated at high resolution. Other parameters 
were set as follows: 156 µm increments, 0° angle, 70 kVp,
114 µA, 0.5 mm Al filter, and a voxel size of 8 µm. The raw 
images were qualitatively investigated for particle distribu-
10 
tion trends, core orientation, and shell-core interaction. In 
addition, qualitative and quantitative assessment of the 
composites was conducted using a built-in 'bone trabecular 
morphometry' analytical tool with a lower threshold level of 
130, gauss sigma of 3 .0, and gauss support of 9. This script 
to surround the core. Blank and simvastatin-loaded shells 
were created using the same method described above for the 
cores, where 1 g of CS was mixed with 800 µL of DI water, 
and in the case of simvastatin-loaded shells, 20 mg of drug 
were directly added. For samples containing metronidazole­
loaded PLGA, the particles were added to both the blank and 
simvastatin-loaded shells at either 1 or 10 wt % and then 
mixed with 850 µL DI water in 3 mL syringes fitted with a 
blunt-tipped needle for easy, consistent filling of the mold. 
Using these formulations for the shells, bilayered compos­
ites were formed by filling the molds about half full. Next, 
15 
prefabricated cores were quickly dipped in DI water to wet 
the surface, which allowed for smooth coverage of the shell 
slurry around the core, inserted into the mold, and pressed 
down onto the metal pegs until they stopped. The pegs 
positioned the cores and held them in place during setting of 20 
the shell slurry. The filled mold was placed into a 37° C.
oven and allowed to dry overnight. For simplification, the 
different types of samples were given abbreviated names 
(Table 1). 
created a three-dimensional reconstruction that allowed 
visual assessment of cross-sections through the composite 
and provided the volume percentage of embedded polymeric 
particles and internal voids. 
Composite Dissolution 
Destructive testing was used to monitor dissolution of the 
bilayered composites. BSBC, 1-BSBC, and 10-BSBC 
samples were weighed, placed in separate 20 mL scintilla­
tion vials containing 12 mL of PBS and incubated on a plate 
shaker at 37° C. Every 4 d, replicate samples of each type
were removed and dried at 43° C. overnight. For the
Note: 
TABLE 1 
Abbreviations for tbe different sample types fabricated. 
Codes are read: BSBC » (B)S(B)C » (Loading) in SHELL, 
(Loading) in CORE. 
Shell Composition 
Blank 
Blank 
Simvastatin 
Simvastatin 
1 wt% PLGA 
1 wt% PLGA 
1 wt % PLGA & Simvastatin 
1 wt % PLGA & Simvastatin 
10 wt% PLGA 
10 wt% PLGA 
10 wt% PLGA & Simvastatin 
10 wt% PLGA & Simvastatin 
No Layer Blank (No Drug) 
Core Composition 
Blank 
Simvastatin 
Blank 
Simvastatin 
Blank 
Simvastatin 
Blank 
Simvastatin 
Blank 
Simvastatin 
Blank 
Simvastatin 
Code 
BSBC 
BSSC 
SSBC 
sssc 
1-BSBC 
1-BSSC 
1-SSBC 
1-SSSC 
10-BSBC 
10-BSSC 
10-SSBC 
10-SSSC 
NL 
PLGA particles contained metronidazole. 
The shells and cores described had a volume ratio of 
50:50. Two other ratios were tested with simvastatin loaded 
into the shell only (SSBC), core only (BSSC), or both layers 
(SSSC). These samples were used to demonstrate how a 
change in the volume ratio would affect drug release from 
the composites. Table 2 lists the volume ratios used and the 
dimensions of the respective core and shell components. 
Custom molds were created to accommodate the different 
sizes, but the rest of the fabrication process was the same as 
described previously. 
TABLE 2 
Shell to core volume ratios and dimensions of 
the bilayered composites 
Shell Core 
Volume Ratio Shell Height Diameter Core Height Diameter 
50:50 12.6 mm 6.3 mm 10 mm 4.7 mm 
70:30 9.6 mm 4.7 mm 6.2 mm 3.2 mm 
85:15 9.6 mm 4.7 mm 6.2 mm 2.4 mm 
25 remaining samples, the PBS was replaced with fresh solu­
tion. The dried samples were weighed to determine the 
amount of material remaining, which was then used to 
calculate the percentage of residual mass. 
30 
Mechanical Properties 
Compression testing was performed to investigate any 
effects on mechanical properties caused by the layered 
geometry, simvastatin directly loaded into CS as well as the 
introduction of PLGA particles into the shell of the com­
posites. All samples types listed in Table 1 were evaluated. 
35 Testing was accomplished using a Bose ELF 3300 system. 
Contact surfaces were lightly sanded, if necessary, to create 
parallel surfaces in contact with the compression platens. All 
samples were loaded at a rate of 0.5 N/sec until failure. 
Compressive modulus (M) and ultimate compressive 
40 strength (UCS) were calculated (Dowling N E. Mechanical 
behavior of materials: engineering methods for deformation, 
fracture, and fatigue. 2 ed. Upper Saddle River, N.J.: Pren­
tice-Hall; 1999). 
Drug Release from Bilayered Composites 
45 Simvastatin Release 
Release of simvastatin was measured for composites 
having shell to core volume ratios of 50:50, 70:30, and 
85:15. BSBC, BSSC, SSBC, and SSSC samples for all 
volume ratios were prepared using the same simvastatin 
50 loading described in section 2.2. Samples were pre-weighed 
and submerged in PBS. Considering the overall size differ­
ences between the sample types, different volumes of PBS 
were used to maintain similar fluid volume to composite 
surface area ratios. To determine suitable sink conditions, 
55 the sample surface area to solution volume ratio of 50:50 
samples was compared to those used in previous research 
(Oreliana B R, Thomas M V, Dziubla T D, Shah N M, Hilt 
J Z, Puleo D A. Bioerodible calcium sulfate/poly(�-amino 
ester) hydrogel composites. J Mech Behav Biomed. 2013; 
60 26:43-53). A small pilot study showed that the dissolution 
rate of 50:50 samples remained constant for volumes above 
10 mL ( data not shown). To avoid saturation of CS or drug 
in PBS, a larger volume (12 mL) was used for the 50:50 
samples. All other samples were placed in 4 mL, similar to 
65 previous release studies (Oreliana B R, Hilt J Z, Puleo D A. 
Drug release from calcium sulfate-based composites. J 
Biomed Mater Res B. 2014). To determine how simvastatin 
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would be released from bilayered composites dissolving in 
non-sink conditions, 50:50 samples were also immersed in 
8 mL of PBS. All samples were incubated at 37° C. on a
plate shaker. Every 4 d, supernatant was collected and 
replenished with fresh PBS. Collected supernatant was 5 
treated with 100% ethanol in a 50:50 volume ratio to make 
sure all simvastatin was in solution. The mixture was then 
0.45 urn-filtered and absorbance measured at 240 nm. 
Multiple Drug Release 
14 
neous but more frequent distribution of particles throughout 
the CS shell (FIG. 3, bottom right). Similar to BSBC, both 
1-BSBC and 10-BSBC had cores that were embedded in the
center of the composite with a parallel orientation to the
outer surface. Additionally, all layered samples had some
minor defects located at the shell/core interface, with most
of these discontinuities occurring near the top and bottom of
the samples.
Quantitative Evaluation
Morphometric analysis was conducted to better assess the 
overall microarchitecture of bilayered CS samples. As 
shown in FIG. 4, the average volume percentage of voids in 
NL samples (0.96%) was significantly lower than that for all 
others (p<0.001). Furthermore, the particle content of 
To investigate the kinetics of metronidazole and simvas- 10 
tatin release from bilayered CS composites, samples were 
pre-weighed, submerged in 12 mL of PBS, and incubated at 
37° C. while on a plate shaker. Supernatant was collected
and replenished every 4 d. Two aliquots from each sample 
were kept for measurement of metronidazole and simvasta­
tin separately. Metronidazole in syringe-filtered (0.45 µm) 
supernatant was assayed directly using UV spectroscopy at 
318 nm. Simvastatin was measured using high performance 
liquid chromatography (HPLC) on a Hitachi Primaide sys­
tem fitted with a Kinetix C18 column (5 µm, 4.6x150 mm). 20 
Prior to measurement, supernatant was mixed with 5 mM 
EDTA (pH 8.0) at a 50:50 volume ratio and allowed to sit 
overnight. EDTA, a common chelating agent, was used to 
remove calcium ions that could precipitate during HPLC 
analysis. Next, this mixture was mixed with 100% ethanol in 
15 10-BSBC samples, 7.59%, was significantly higher 
(p<0.001) than that of both BSBC and 1-BSBC. Percentages 
for BSBC (3.30%) and 1-BSBC ( 4.52%) were not signifi­
cantly different. 
Composite Dissolution 
Loading 1 wt % of PLGA particles into the shells of 
bilayered composites did not have a significant effect on the 
dissolution rate (-3.1 %/d) (FIG. 5). Increasing the loading to 
10 wt % PLGA, however, significantly increased the disso­
lution rate to -3.43%/d (p<0.001), even though the time for 
25 complete dissolution differed by only about 4 d. 
Mechanical Properties of Layered CS 
Fabrication oflayered structures significantly affected the 
mechanical properties of CS composites (FIG. 6). The 
ultimate compressive strength of NL (5.40±0.38 MPa) 
a 50:50 volume ratio to ensure complete dissolution of the 
poorly soluble simvastatin. The final sample composition 
was 25% supernatant, 25% EDTA, and 50% ethanol. A 
70:30 (acetonitrile: DI water+0.01 % trifluoroacetic acid) 
isocratic mobile phase at a flow rate of 1 mL per minute was 
used. Simvastatin was detected at 240 nm. 
Statistics 
Statistical analysis of the results was conducted using 
either a two-tailed unpaired t-test or one-way ANOVA. As 
appropriate, a Tukey-Kramer multiple comparison post hoc 
test was implemented. Linear regression was performed on 
sustained release profiles and the calculated slopes com­
pared for significant differences using a two-tailed t-test. 
Differences between groups were considered to be signifi­
cant with p-values <0.05. 
30 samples was not significantly higher than that of BSSC 
(4.14±0.75 MPa) and 1-BSBC (4.33±0.72 MPa), but it was 
significantly greater than that for BSBC (3.80±0.46 MPa, 
p<0.01) and all other bilayered samples (p<0.001) (FIG. 
6A). Within subgroups for PLGA particle loading, the 
35 strength of 1-BSBC (4.33±0.72 MPa) was significantly 
higher than that for both 1-SSSC (3.03±0.2 MPa) and 
10-BSSC (3.03±0.4 MPa) (p<0.05). There were no other
significant differences seen for layered samples, both loaded
with PLGA and without.
40 
Metronidazole-Loaded PLGA Particles 
Metronidazole-loaded PLGA particles alone were first 
evaluated to determine how well the polymer controlled 
drug release. According to the results in FIG. 2, metronida­
zole was released steadily during the first 3 hr at a rate of 45 
about 4 µg per minute. Only about 8% of the drug was 
released during the first hr. After 3 hr, 30% of the total 
loading of metronidazole had been released. From this point 
forward, the release of drug from the particles slowed, with 
roughly 35% of the loaded metronidazole released after 6 hr. 50 
Composite Microarchitecture 
Qualitative Evaluation 
MicroCT images showed the CS cores embedded within 
the layered composites and their interaction with the CS 
shells, as well as the distribution of PLGA particles embed- 55 
ded in the shells (FIG. 3). For comparison, results for a CS 
sample without layers (NL) are included. Minor defects 
(bubbles and other discontinuities) were found throughout 
the CS matrix in all samples. These defects were nearly 
spherical in nature and, thus, easily distinguishable from 60 
PLGA particles, which were irregularly shaped. The blank 
(drug-free) layered samples, BSBC, showed the CS core 
embedded within the CS shell and oriented parallel to the 
outer walls. The distribution of 1 wt % PLGA particles in the 
shells of 1-BSBC samples appeared to be homogeneous but 65 
sparse (FIG. 3, top right). In 10-BSBC samples with 10 wt 
% loading of particles in the shells, there was a homage-
The compressive elastic modulus ofNL (712±139.6 MPa) 
was significantly higher (p<0.001) than that for SSBC 
(250±37.6 MPa), 1-BSBC (172±96.9 MPa), 1-SSSC 
(162±70.4 MPa), 10-BSBC (237±84.2 MPa), 10-BSSC 
(154±58.4 MPa), 10-SSBC (216±87.8 MPa), and 10-SSSC 
(184±29.6 MPa) bilayered samples (FIG. 68). The average 
modulus of the blanks was also significantly greater than 
those of SSSC (306±157.6 MPa, p<0.01) and 1-SSBC 
(391±282 MPa, p<0.05). BSSC (495±184 MPa) samples 
had a significantly higher (p<0.05) modulus than did 
1-BSBC (172±97 MPa), 1-SSSC (162±70 MPa), and
10-BSSC (154±58 MPa). There were no other significant
differences between layered samples and their subgroups.
Drug Release from Bilayered Composites
Simvastatin Release
To demonstrate temporally controlled release of simvas­
tatin using bilayered composites, several experiments were 
conducted using different shell to core volume ratios. FIG. 
7A shows the cumulative release of simvastatin from com­
posites that had an 85: 15 shell to core volume ratio. The 
sustained release of drug from samples with simvastatin 
loaded into both shell and core (SSSC), 0.055 mg/d, was 
significantly faster (p<0.001) than for SSBC (0.043 mg/d) 
and SSBC+BSSC (0.046 mg/d). Minimal drug loaded into 
the core only (BSSC) was released during the first 24 d. 
From that point until the samples dissolved, however, 
release of simvastatin from CS cores increased to 18 µg/d, 
whereas release from SSBC samples was finished. The total 
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amount of simvastatin released from BSSC (shell) and 
SSBC (core) samples was 0.24±0.05 mg and 1.19±0.01 mg, 
respectively. The rate of release from BSSC was signifi­
cantly slower than that for both SSSC (p<0.05) and SSBC+ 
BSSC (p<0.01). 
FIG. 78 shows the results for simvastatin released from 
composites consisting of 70% shell volume and 30% core 
volume. Over the first 20 d, the drug release rate from SSBC 
(0.046 mg/d) was significantly faster (p<0.01) compared to 
0.041 mg/d for SSSC. Little to no drug was released from 
BSSC samples during the first 20 d, followed by an upward 
shift to a rate of 0.022 mg/d, which was significantly slower 
than the rates for both SSSC and SSBC+BSSC (p<0.01 ). For 
BSSC samples, 0.32±0.03 mg of drug was released. After 20 
d of simvastatin release from SSBC samples, the shells had 
completely dissolved and released 1.30±0.07 mg of simv­
astatin. 
The results for release of simvastatin from composites 
with a 50:50 shell to core volume ratio are depicted in FIG. 
7C. For the first 16 d of the experiment, the rate of release 
from SSBC composites, 0.095 mg/d, was significantly 
slower (p<0.05) than that for SSSC (0.13 mg/d) and SSBC+ 
BSSC (0.12 mg/d). During the same period, a small amount 
of drug was released from BSSC at a slow rate of 0.025 
mg/d. After 16 d and until the composites dissolved, the rate 
of drug release from SSBC samples gradually slowed as the 
shell finished dissolving, a trend similar to what was 
observed in both FIGS. 7A and 78. A total of 1.52±0.3 mg 
of drug was released from the shell. At its peak, the rate of 
release from BSSC samples, 0.10 mg/d, was not signifi­
cantly different from the rates observed for SSSC and 
SSBC+BSSC samples, ultimately releasing a total 
1.44±0.24 mg of simvastatin. 
16 
Multiple Drug Release 
FIG. 9 shows results for release of metronidazole from 
PLGA particles embedded in CS shells as well as the release 
of simvastatin directly loaded in the shell or core of bilay-
5 ered composites. The samples used for this experiment had 
a 50:50 shell to core volume ratio. Based on this ratio and 
the dissolution results presented in FIG. 5, the shell and core 
portions of the composites were predicted to dissolve com­
pletely in 14-16 d of the 28-32 d dissolution period for the 
10 
complete composite. For composites with 1 wt % PLGA 
particles embedded in CS, a large amount of metronidazole 
(65%) was initially released from the shells during the first 
4 d at a  rate of 16.3%/d (FIG. 9A). After the initial burst of 
metronidazole, the release of drug slowed to a rate of 4.0%/d 
and continued to slowly decay to zero until the shells 
15 completely dissolved. Composites with 10 wt % PLGA 
particles showed a similar burst of metronidazole during the 
first 4 d, with as much as 55% of the total drug released 
(FIG. 98). The rate of release of metronidazole decayed 
from 13.7%/d through the first 4 d, to 6.7%/d from days 4-8, 
20 and finally down to 0% by d 12 of the release. The results 
in FIG. 9 were normalized based on the amount of drug 
loaded into the respective layer rather than the complete 
composite. This allowed for direct comparison of the tem­
poral release observed between metronidazole and simvas-
25 tatin. When simvastatin was loaded into only the shell for 1 
wt % and 10 wt % PLGA composites, metronidazole was 
initially released at a higher rate than simvastatin (2-6.3%/ 
d). Because of the slow initial rate of simvastatin release, a 
short lag in the release profile developed, creating separation 
30 from the metronidazole profile and allowing for simvastatin 
to be released for up to 8 d longer. When the drugs were 
separated by keeping metronidazole-containing PLGA par­
ticles in the shell and loading simvastatin in only the core, 
80-90% of the metronidazole was released over approxi-
35 mately 12 d before trace amounts of simvastatin were 
detected. After 16 d, the shells had completely dissolved, 
and metronidazole was no longer detected. In addition, the 
majority of simvastatin, isolated to only the core, was 
released starting after 12 d. Due to the layers separating the 
The total amount of simvastatin released from the cores 
(BSSC) for 50:50 (1.44±0.24 mg) samples was significantly 
different (p<0.001) than that for samples with either a 70:30 
(0.32±0.03 mg) or 85: 15 (0.24±0.05 mg) shell to core 
volume ratio. There was no significant difference in the total 
drug release between the 70:30 and 85:15 BSSC samples. 
For 50:50 SSBC samples, the total amount released 
(1.52±0.3 mg) from the shells was significantly different 
(p<0.001) than for 70:30 SSBC (1.30±0.07 mg) and 85:15 
SSBC (1.19±0.1 mg) samples. In addition, the total amount 45 
of drug released from 70:30 SSBC samples was significantly 
different than from 85:15 SSBC samples (p<0.01). When 
comparing the total amount of drug released when SSBC 
and BSSC results are combined (SSBC+BSSC) to the total 
amount of drug released from SSSC samples, SSBC+BSSC 50 
specimens with an 85:15 shell to core volume ratio had a 
total combined release that was significantly lower (p<0.01) 
than the total amount of simvastatin released from the SSSC 
with the same volume ratio. 
40 two drugs, a sequential release was observed with all met­
ronidazole drug released prior to simvastatin. 
Metronidazole-Loaded PLGA Particles 
A previous study showed that loading a hydrophilic drug 
into carrier particles prior to embedding into a CS matrix 
significantly reduced the burst release witnessed when the 
drug was directly loaded into CS (Oreliana B R, Hilt J Z, 
Puleo D A. Drug release from calcium sulfate-based com­
posites. J Biomed Mater Res B. 2014). Therefore, biode­
gradable PLGA microparticles were employed for the cur­
rent study to assist with the sustained release of 
metronidazole from bilayered composites. Because the par-
ticles were exposed to water during the setting phase of CS, 
a release study was conducted using a larger volume of 
water than present during composite formulation to monitor 
55 the potential for premature release of drug from PLGA. No 
initial burst of drug was observed, indicating that the major­
ity of the drug was contained within the PLGA micropar­
ticles during the formation of the composites. 
By reducing the volume of PBS from 12 mL to 8 mL, the 
dissolution time of samples having a 50:50 shell to core ratio 
was doubled (FIG. 8). During the first 32-36 d of incubation, 
simvastatin was released from both SSSC and SSBC 
samples at a rate of 0.074 mg/d and 0.077 mg/d, respec­
tively. Also, a small amount of drug from BSSC samples was 60 
released during the same time frame at a rate of 0.009 mg/d. 
From day 36 until the end of the experiment (68 d), the rate 
for the SSSC samples continued steadily, however the rate 
of release from SSBC decreased to zero around 48 d. 
Additionally, the rate of release from BSSC samples 65 
increased to 0.051 mg/d and remained at this rate until the 
samples finished eroding. 
Composite Microarchitecture 
Qualitative assessment of the morphology of bilayered 
composites showed good distribution of PLGA micropar­
ticles embedded into CS shells at 1 and 10 wt %. The initial 
CS slurry was kept sufficiently fluid to prolong the working 
phase and allow for easy filling of the molds yet viscous 
enough to suspend PLGA particles during the setting phase. 
This trend has been shown in previous research in which 
hydrogel particles were uniformly distributed throughout a 
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CS matrix using similar powder to liquid volume ratios 
(Oreliana B R, Thomas M V, Dziubla T D, Shah N M, Hilt 
18 
J Z, Puleo D A. Bioerodible calcium sulfate/poly(�-amino 
ester) hydrogel composites. J Mech Behav Biomed. 2013; 
26:43-53). Another study, showed the exposure of particles 5 
at or near the surface before dissolution followed the pitting 
those of tissue at the implantation site. CS has been 
described as having properties being similar to cancellous or 
trabecular bone (Hak D J. The Use of Osteoconductive Bone 
G raft Substitutes in Orthopaedic Trauma. J AmAcad Orthop 
Sur. 2007; 15:525-36). Investigating the mechanical prop­
erties of human trabecular bone from the mandible, Misch et 
of CS resulting from the release of particles from those 
locations after a short duration submerged in PBS (Oreliana 
B R, Hilt J Z, Puleo D A. Drug release from calcium 
sulfate-based composites. J Biomed Mater Res B. 2014). 10 
With the aid of small, metallic pegs, which were removed 
after fabrication, preformed blank and simvastatin-loaded 
cores were positioned in the center of the composites. Small 
defects were observed along the shell/core boundary. Many 
al. measured an ultimate compressive strength of 3.9±2.7 
MPa and elastic modulus of 96.2±40.6 MPa (Misch CE, Qu 
Z, Bidez M W. Mechanical properties of trabecular bone in 
the human mandible: Implications for dental implant treat­
ment planning and surgical placement. J Oral Maxi! Surg. 
1999; 57:700-6). The introduction of a bilayered geometry 
significantly affected properties compared to solid CS 
samples, with up to a 44% and 78% reduction in the strength 
and elastic modulus, respectively. Note, however, that the 
properties of the layered composites were comparable to 
of these were air bubbles trapped as the CS set. Larger 15 
bubbles that appeared to accumulate near one end of the 
samples along the shell/core interface were most likely 
caused by an air pocket created when the cores were pressed 
into CS slurry. 
those of trabecular bone. The decrease in strength compared 
to the samples without layers could be due to the small air 
pockets along the shell/core interface acting as discontinui­
ties within the composite, both at the interface parallel to the 
central axis of the cylinder as well as at the ends of the core. 
Quantitative measurements assessed the particle volume 20 
fraction of bilayered CS composites. Although a significant 
increase in porosity was seen between samples containing 1 
wt% and 10 wt% PLGA, the difference was not 10-fold. 
This lack of separation could be due to other defects, such 
These stress concentrators contributed to a 17-44% decrease 
in the overall strength of the composites. The addition of 
either 1 or 10 wt% PLGA particles to CS shells did not have 
an effect when compared to blank bilayered samples. In 
previous research, as much as a 50-60% reduction in 
as air pockets found along the shell/core interface. The script 25 
used to calculate the porosity is limited to only distinguish­
ing between what is solid and what is not. The introduction strength was seen following the addition of 10 wt% of gel 
particles to the monolithic CS matrix (Orellana BR, Thomas 
M V, Dziubla T D, Shah N M, Hilt J Z, Puleo D A. 
of bubbles adds error to the calculations because these 
imperfections show up as radiolucent spaces similar to 
PLGA particles. Comparing the solid and layered samples 
demonstrates that defects strongly influenced on the porosity 
calculations. 
Composite Dissolution 
Calcium sulfate is a dense material that dissolves via 
surface erosion (Oreliana B R, Thomas M V, Dziubla T D, 
Shah N M, Hilt J Z, Puleo D A. Bioerodible calcium 
sulfate/poly(�-amino ester) hydrogel composites. J Mech 
Behav Biomed. 2013; 26:43-53; Thomas M V, Puleo D A. 
Calcium sulfate: properties and clinical applications. J 
Biomed Mater Res B. 2009; 8 8 6:597-610). Although the 
embedded PLGA particles were distributed throughout the 
CS matrix, they did not appear to be interconnected, which 
otherwise would have allowed for fluid to seep into the 
composite. During erosion, closed pockets with PLGA par­
ticles near the surface were exposed, releasing the polymer 
particles and increasing the surface area for further disso­
lution. Consequently, as the composites dissolved and 
PLGA particles were released, the surface area to volume 
ratio increased, allowing for faster dissolution of CS. Fur­
thermore, because embedded PLGA particles did not change 
the dissolution characteristics of CS, the shorter lifespan 
when 10 wt % particles were added was related to the 
smaller overall volume of CS per sample that needed to 
dissolve. These trends have also been witnessed in a previ­
ous study in which dissolution of CS was observed after 
hydrogel particles were uniformly distributed throughout the 
composite (Oreliana B R, Thomas M V, Dziubla T D, Shah 
N M, Hilt J Z, Puleo D A. Bioerodible calcium sulfate/poly 
(�-amino ester) hydrogel composites. J Mech Behav 
Biomed. 2013; 26:43-53). Thus, the presence of polymer 
particles, even having different chemistries, affected only the 
duration of dissolution, depending on the amount of par­
ticles loaded, and not the nature of the dissolution process 
itself. 
Mechanical Properties of Layered CS 
To be a suitable alternative to autologous bone, the ideal 
synthetic material would have characteristics similar to 
30 Bioerodible calcium sulfate/poly(�-amino ester) hydrogel 
composites. J Mech Behav Biomed. 2013; 26:43-53). In the 
present study, the PLGA particles were isolated to only the 
shell of the composites. Also, the presence of a solid blank 
core may have provided reinforcement for the composite, 
35 which may allow a greater range of PLGA particle loading 
that would provide greater control over the drug dose within 
the composites. 
The loading of simvastatin directly into the shell, core, or 
both layers generally did not significantly affect the strength 
40 of the bilayered composites, even though isolated differ­
ences were observed (1-BSBC versus 1-SSSC and 
10-BSSC). In another experiment conducted by Oreliana et
al., loading of simvastatin directly into monolithic CS did
not have a significant effect on the strength of the samples
45 (Oreliana B R, Hilt J Z, Puleo D A. Drug release from 
calcium sulfate-based composites. J Biomed Mater Res B. 
2014). Another group determined that up to 10% loading of 
simvastatin into calcium phosphate samples did not signifi­
cantly affect the compressive strength (Yin H, Li Y G ,  Si M, 
50 Li J M. Simvastatin-loaded macroporous calcium phosphate 
cement: Preparation, in vitro characterization, and evalua­
tion of in vivo performance. J Biomed Mater Res A. 2012; 
lOOA:2991-3000). The present study had a lower loading of 
simvastatin (i.e., 2 wt%), however. Thus, direct loading of 
55 simvastatin does not affect the overall strength of different 
materials. 
Drug Release from Bilayered Composites 
The layered geometry used for the CS samples provided 
a unique platform for achieving a customizable sequential 
60 release of therapeutic agents. Loading of PLGA micropar­
ticles into the CS matrix allows for further tailoring of drug 
release. 
Simvastatin Release 
The present experiments were designed to demonstrate 
65 how the release of simvastatin can be tailored depending on 
which layer the drug was loaded in, whether it was the shell 
only, core only, or both. Furthermore, to illustrate the ability 
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to adjust the duration or even the delay of drug release from 
either the shell or core, the shell to core volume ratio was 
altered. However, there were limitations to how much the 
volume ratio could be adjusted. For instance, the 50:50 shell 
to core ratio was considered the maximum. With the present 5 
dimensions, increasing the core volume beyond this point 
would create a thin and unstable shell. On the other hand, if 
the ratio was made so the shell would be greater than 85% 
of the total volume, the local concentration of drug released 
from the core could be too low to be therapeutically relevant. 10 
For all of the release profiles that had simvastatin loaded 
in only the cores, there was a small amount of drug released 
from the start of composite dissolution up to when the core 
was completely exposed. Because the cores were suspended 
using a small metal peg that was later removed after the 15 
samples were fabricated, the hole that remained may have 
been large enough to allow a noticeable, but statistically 
insignificant, amount of simvastatin to be released. 
In addition to investigating the effects of adjusting the 
shell to core volume ratio, the volume of PBS used for the 20 
release study was reduced from 12 mL to 8 mL. Because of 
the possible diverse environments in various implantation 
sites, it is likely for the implant to encounter different fluid 
volumes and/or turnover rates that may not allow for sink 
conditions. A small study demonstrated how release of 25 
simvastatin would change under non-sink conditions. To 
conduct the comparison, the 50:50 volume ratio was used. 
Interestingly, even with the reduction in the volume of PBS 
to 8 mL, the transition after shell depletion to core only 
erosion occurred around the halfway point, similar to the 30 
results seen under sink conditions. In previous work, the 
effects of fluid volume on the dissolution of CS were 
investigated (Orellana BR, Thomas M V, Dziubla TD, Shah 
N M, Hilt J Z, Puleo D A. Bioerodible calcium sulfate/poly 
(�-amino ester) hydrogel composites. J Mech Behav 35 
Biomed. 2013; 26:43-53). It was determined that the change 
in volume of fluid or even the turnover rate could have a 
large effect on the dissolution of CS (Orellana B R, Thomas 
M V, Dziubla T D, Shah N M, Hilt J Z, Puleo D A. 
Bioerodible calcium sulfate/poly(�-amino ester) hydrogel 40 
composites. J Mech Behav Biomed. 2013; 26:43-53). The 
duration of drug release can be greatly prolonged ( doubled 
in the present study) using different fluid volumes. McLaren 
et al. also observed a large difference in the rate of drug 
release from calcium sulfate pellets when the fluid was 45 
completely refreshed at each time point versus exchanging 
only a fraction of the fluid volume (McLaren A C, McLaren 
20 
completely dissolved. Controlled release of metronidazole 
from PLGA microspheres after an initial burst has been 
described as a possible treatment for periodontal disease 
(Tiwari G .  Treatment Of Periodontal Diseases: Formulation 
consideration. Int J Phann Bio Sci). By embedding particles 
into a CS matrix, the release of metronidazole was con-
trolled throughout the first 16 d of the present study. In 
addition, previous research has demonstrated that drug­
loaded hydrogel particles homogeneously distributed 
throughout a CS matrix allowed for a controlled release of 
drug, which only occurred due to the breakdown of particles 
exposed at the surface of the dissolving composite (Orellana 
B R, Thomas M V, Dziubla T D, Shah N M, Hilt J Z, Puleo 
D A. Bioerodible calcium sulfate/poly(�-amino ester) 
hydrogel composites. J Mech Behav Biomed. 2013; 26:43-
53; Orellana B R, Hilt J Z, Puleo D A. Drug release from 
calcium sulfate-based composites. J Biomed Mater Res B. 
2014). 
With the intended use of these composites as a grafting 
substitute for alveolar bone augmentation, the oral cavity 
presents challenges for proper tissue regeneration due to the 
environment being rich with bacteria that can colonize 
natural and synthetic substrates. Thomas and Puleo 
described the implications of infection and inflammation in 
periodontal disease and tissue regeneration (Thomas M, 
Puleo D. Infection, Inflammation, and Bone Regeneration a 
Paradoxical Relationship. J Dent Res. 2011; 90:1052-61). 
Currently, the standard treatment for infected periodontal 
defects has antimicrobial agents being administered, either 
systemically or locally, prior to implantation of grafting 
material, which only delays the overall recovery of lost 
tissue (Nguyen A, Kim S, Maloney W, Wenke J, Yang Y. 
Effect of coadministration of vancomycin and BMP-2 on 
cocultured Staphylococcus aureus and W-20-17 mouse bone 
marrow stromal cells in vitro. Antimicrob Agents Ch. 2012; 
56:3776-84; Lee F-Y, Chen D, Hu C-C, Hsieh Y-T, Liu S-J, 
Chan E-C. In Vitro and In Vivo Investigation of Drug­
Eluting Implants for the Treatment of Periodontal Disease. 
AAPS PharmSciTech. 2011; 12:1110-5; Bernimoulin J P. 
Repeated local metronidazole-therapy as adjunct to scaling 
and root planing in maintenance patients. J Med Microbial. 
1999; 26:710-5). Administration of antimicrobial agents 
allows for better bone formation. Chen et al. investigated the 
effects of two different growth factors in a chronically 
infected bony defect in rat femurs (Chen X, Schmidt AH, 
Tsukayama D T, Bourgeault CA, Lew W D. Recombinant 
Human Osteogenic Protein-I Induces Bone Formation in a 
Chronically Infected, Internally Stabilized Segmental 
Defect in the Rat Femur. J Bone Joint Surg. 2006; 88:1510-
23). Although some healing occurred in the infected sites, 
the extent of bone formation was greater with the systemic 
administration of antibiotics (Chen X, Schmidt A H, Tsu­
kayama D T, Bourgeault C A, Lew W D. Recombinant 
Human Osteogenic Protein-I Induces Bone Formation in a 
S G ,  Nelson C L, Wassell D L, Olsen K M. The effect of 
sampling method on the elution of tobramycin from calcium 
sulfate. Clinical orthopaedics and related research. 2002:54- 50 
7). In the present study, although the rate of release slowed, 
the mechanism of drug release remained dependent on 
dissolution of CS. This could allow for tailoring of drug 
loading and/or the sample geometry according to the physi­
ological conditions expected at the implant site. 55 Chronically Infected, Internally Stabilized Segmental 
Defect in the Rat Femur. J Bone Joint Surg. 2006; 88:1510-
23). To further enhance the process of fighting infection and 
then regenerating lost tissue, release of an anti-bacterial 
Multiple Drug Release 
A multiple drug release study was conducted to investi­
gate the release kinetics of bilayered composites loaded with 
an antimicrobial agent and an osteogenic agent. Findings for 
samples with metronidazole in PLGA particles and simvas- 60 
tatin directly loaded into CS demonstrated sequential 
release. Polymeric particles loaded with metronidazole and 
embedded into the shell were exposed as CS experienced 
surface erosion, and sustained release of the drug occurred 
as the PLGA particles subsequently degraded. Release from 65 
both 1 and 10 wt % particles embedded into the CS shell was 
sustained until the shell portion of the bilayered composites 
agent from the graft starting at the time of implantation may 
prove beneficial to help reduce the overall healing time. 
Many studies have investigated dual purpose implantable 
scaffolds, but none have employed a concentric cylindrical 
CS system as described in the present studies. Reis et al. 
developed drug-free, bilayered membranes comprising a 
continuous outer layer of PLGA with a porous calcium 
phosphate inner layer for the regeneration of lost periodontal 
tissue (Carlo Reis E C, Borges A P B, Araujo M VF, Mendes 
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V C, Guan L, Davies J E. Periodontal regeneration using a 
bilayered PLGA/calcium phosphate construct. Biomaterials. 
2011; 32:9244-53). For infected sites, Nguyen et al. devel­
oped a co-culture model using methicillin-sensitive Staphy­
lococcus aureus and mouse bone marrow stromal cells to 5 
investigate the dual effects of an antibiotic, vancomycin, 
along with bone morphogenetic protein-2 (BMP-2) (Nguyen 
22 
for treating infected bony defects, e.g., periodontal pockets. 
Although the shell and core geometry reduced mechanical 
strength of the composites, the properties were similar to 
A, Kim S, Maloney W, Wenke J, Yang Y. Effect of coad­
ministration of vancomycin and BMP-2 on cocultured 
Staphylococcus aureus and W-20-17 mouse bone marrow 
stromal cells in vitro. AntimicrobAgents Ch. 2012; 56:3776-
84). Separately, the two agents were not effective, but when 
delivered together, the needed concentration of vancomycin 
was significantly reduced, suggesting that lower, non-toxic 
doses could be used (Nguyen A, Kim S, Maloney W, Wenke 15 
J, Yang Y. Effect of coadministration of vancomycin and 
BMP-2 on cocultured Staphylococcus aureus and W-20-17 
mouse bone marrow stromal cells in vitro. Antimicrob 
Agents Ch. 2012; 56:3776-84). An in vivo study in which 
vancomycin and BMP-2 were delivered simultaneously 20 
from a biodegradable polyurethane scaffold demonstrated 
that bone formation could be regenerated within an infected 
defect (Guelcher SA, Brown KV, Li B, Guda T, Lee B H, 
Wenke J C. Dual-purpose bone grafts improve healing and 
reduce infection. J Orthop Trauma. 2011; 25:477-82). How- 25 
ever, these systems release the drugs simultaneously. Con­
sidering the intent for the current device to help streamline 
the existing treatment process, it was encouraging to see 
metronidazole released before simvastatin, even when 
loaded into the shell together. The difference in the release 30 
kinetics can be explained primarily by the way the two drugs 
were loaded. Previous work has shown that release of drug 
from polymer particles embedded into a CS matrix had a 
rapid, initial burst followed by decay in the rate of release 
(Oreliana B R, Thomas M V, Dziubla T D, Shah N M, Hilt 35 
J Z, Puleo D A. Bioerodible calcium sulfate/poly(�-amino 
ester) hydrogel composites. J Mech Behav Biomed. 2013; 
26:43-53; Oreliana B R, Hilt J Z, Puleo D A. Drug release 
from calcium sulfate-based composites. J Biomed Mater Res 
those for mandibular trabecular bone. This may be an 
important trait that could allow for these implants to better 
mimic the surrounding target tissue being treated. Changing 
the shell to core volume ratio dictates the duration of drug 
release from each layer. When metronidazole and simvas­
tatin were loaded together in the shell or in separate layers, 
10 
temporal separation of the two drugs was achieved. Being 
able to tune such as system may help streamline the multiple 
steps needed to regenerate tissues more efficiently. 
B. 2014). The lower rate is attributed to the decrease in 40 
surface area as CS degrades, leading to a smaller volume of 
particles exposed at the surface over time (Orellana B R, 
Thomas M V, Dziubla T D, Shah N M, Hilt J Z, Puleo DA. 
Bioerodible calcium sulfate/poly(�-amino ester) hydrogel 
composites. J Mech Behav Biomed. 2013; 26:43-53; Orel- 45 
lana B R, Hilt J Z, Puleo D A. Drug release from calcium 
sulfate-based composites. J Biomed Mater Res B. 2014). 
Simvastatin, on the other hand, is directly mixed with CS 
during sample formation, and due to the hydrophobic nature 
Example 2 
Blank Samples 
Bilayered calcium sulfate (CS) composites were produced 
according to FIGS. 1 and 10. CS slurries were prepared by 
mixing 1 gram CS powder with 800 µL of deionized water 
(DI). To create cores, prepared CS slurry was injected into 
a Teflon mold and kept at 43° C. for 24 hrs. Finished cores
were suspended on a peg to center in a larger mold that 
allowed for a CS mixture to be injected, completely sur-
rounding the CS core. 
Drug Loaded Samples 
To test the release of a bioactive agent from different CS 
layers, 20 mg (2 wt % ) of simvastatin was directly mixed 
into 1 g of CS and combined with 800 µL DI and used to 
produce either the shell only loading (SSBC), core only 
loading (BSSC), or both shell and core loading (SSSC). For 
samples containing PLGA loaded with 12.5 wt% metron­
idazole, the particles were added to both the blank and 
simvastatin-loaded shells at either 1 or 10 wt % and then 
mixed with 850 µL DI water in 3 mL syringes fitted with a 
blunt-tipped needle for easy, consistent filling of the mold. 
Bilayered Calcium Sulfate/Calcium Phosphate Composites 
To enhance mechanical stability, dicalcium phosphate 
dihydrate (DCPD) was added to the bilayered implants 
(FIG. lOb). CP slurries were prepared by combining 1 g 
DCPD (a mixture of monocalcium phosphate monohydrate 
and �-tricalcium phosphate with a 1: 1 molar ratio) powder 
and 400 µL of 100 mM sodium citrate. Cores with either CS 
or DCPD slurries were packed into a mold and kept in either 
a 43° C. oven or a desiccator under vacuum for 24 hr,
respectively. Finished cores were inserted in a larger mold 
that allowed for a slurry mixture to be packed around the 
cores. Final samples consisted of CP blanks, CP-shell/CS­
core, and CS-shell/CP-core. 
The process illustrated in FIG. 10 depends on a variety of 
parameters, including but not limited to: 
Slurry mixture for calcium sulfate composites is fluid 
enough to be injected allowing for consistent easy 
filling of the molds. 
To suspend the calcium sulfate cores small metallic pegs 
were inserted allowing for accurate and consistent 
orientation. Pegs were removed before testing. 
For calcium sulfate/calcium phosphate implants, prefab­
ricated DCPD cores were correctly oriented in the mold 
for shell production via a small insert located on the 
bottom plate of the mold. 
of the drug, it does not become segregated to the surface 50 
during the setting of CS. The release of simvastatin is, 
therefore, governed by the surface erosion characteristics of 
CS, which were shown to be linear. This allowed for a near 
constant rate of release of simvastatin. These differences in 
release kinetics between the two drugs and their means of 55 
loading allowed for enough separation for all the metron­
idazole to be released 4 d sooner than simvastatin. When 
simvastatin was loaded into only the core while PLGA 
particles loaded with metronidazole remained in the shell, 
there was a much greater lapse in time for a fully separated 60 
sequential release to occur, which may be useful for mim­
icking the clinical sequence of events for treating infection 
and subsequently restoring lost or damaged tissue. 
DCPD was packed under pressure into the molds. 
Although the compressive properties decreased with the 
introduction of a layered geometry, the resulting strengths 
65 for calcium sulfate bilayered composites remained either 
similar to or stronger than the strength of trabecular bone in 
the mandible. Calcium sulfate/calcium phosphate samples 
In the present study, novel bilayered CS composites were 
investigated for their ability to provide tailored release of 
therapeutic agents as well as a sequential release of different 
drugs. Such a system may be useful as a bone graft substitute 
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were even stronger still. Further, preformed scaffolds can be 
designed to allow fabrication of a variety of shapes. 
Mechanical testing was measured using a Bose ELF 3300 
system and demonstrated the ultimate compressive strength 
(UCS) and compressive elastic modulus (M) of the materials 5 
(FIG. 18). These data demonstrate the effect of the bilayered 
geometry compared to the single layer samples and trabe­
cular bone. Further, microcomputed Tomography (microCT) 
demonstrated the structural integration of the layered com­
ponents and allowed for analysis of structural changes 10 
during the erosion of the bilayered materials (FIG. 11). 
Tests were also performed on the destructive degradation 
of the bilayered composites. These data allowed for the 
evaluation of the erosion process of the samples. Samples 
were weighed and placed in separate plastic vials containing 15 
4 mL of PBS, and all the samples were incubated on a shaker 
plate at 37° C. Every 4 days replicate samples were collected
and dried at 43° C. for a minimum of 24 hours. Dried
samples were weighed to determine mass loss. FIG. 19 
shows representative data for mass loss and pH. The erosion 20 
pattern of the layered materials has potential for erosion 
tuning and customizable drug release that could be useful for 
a bone graft substitute. 
24 
center of a wider Teflon mold of height 6.5 mm and diameter 
4.75 mm. The samples were held in place using thin molds 
of equivalent diameter. CS slurries were then prepared with 
some as blanks and some with 1 wt % of simvastatin to form 
a simvastatin loaded CS shell (CSs). The slurries were then 
injected around the DCPD samples and any trapped air was 
removed tapping the mold on a hard surface as the slurry 
sets. The samples were kept in a dry environment at 42
° C.
as they set. The resulting bilayered samples were carefully 
removed from their mold and any DCPD extruding from the 
CS was sanded down. Samples were then removed and 
stored in a dry environment at room temperature. 
For the preparation of DCPD-shell-CS-core (CP/CS) 
samples, DCPD slurries were prepared with and without the 
addition of 2 wt % simvastatin. The slurry is then packed 
into a cylindrical Teflon mold of height 6.5 mm and diameter 
4.75 mm with a 10 mm height and 2.35 mm diameter steel 
dowel rod held in place in the center with a thin mold of 
equivalent diameter. After being packed, the cement was 
allowed to set in a fume hood at room temperature for 24 hrs. 
The dowel rods were then punched out carefully without 
significantly damaging the DCPD shell. CS slurries were 
then prepared with and without the addition of 1 wt % 
simvastatin. The slurries were then injected at the center of 
Example 3 
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25 the DCPD shell. Any trapped air was removed by tapping 
the mold on a hard surface as the slurry sets. The samples 
were kept in a dry environment at 42° C. as they set. The
resulting bilayered samples were carefully removed from 
their mold. Samples were then removed and stored in a dry 
environment at room temperature. 
Simvastatin Release Study 
Release studies were conducted on DCPD samples at 
simvastatin loadings of 1, 2, or 4.8 wt% (CP-1, CP-2, and 
CP-4.8, respectively). The same was done for CS samples 
but only at 1 wt% (CS-1). Blanks of CS and DCPD were 
made for comparisons. Studies on release of bilayered 
CP/CS and CS/CP samples were conducted with drug load­
ings and layering of CS/CPs, CPs/CS, CPs/CSs and CSs/ 
CPs. DCPD layers were 2 wt % and CS layers with 1 wt %. 
CS slurries were prepared by mixing 1 gram calcium 
sulfate hemihydrate (Sigma-Aldrich) with 800 µL of deion- 30 
ized (DI) water. To test the release of a bioactive agent, 10 
mg (1 wt % ) of simvastatin was directly mixed into the CS 
prior to addition of water. CS blanks were also made without 
the addition of simvastatin The CS slurry was then injected 
into a cylindrical Teflon mold of average height 6.5 mm and 35 
diameter 4.75 mm and then kept at 43° C. for 24 hrs. Any
trapped air was removed by tapping the mold on a hard 
surface as the slurry sets. CS samples were then removed 
and stored in a dry environment at room temperature. CS 
samples had an average dry weight of 0.10±0.02 g. 40 All release studies were performed using 4 mL phosphate­
buffered saline (PBS), pH 7.4, at 37° C. and on a plate
shaker. At the end of every 4 days, samples were transferred 
into new vials with 4 mL of PBS and the supernatant from 
Adapting from what was originally proposed by Lemaitre 
et al. (Lemaitre, J.; Mirtchi, A. A.; Mortier, A. Calcium 
phosphate cements for medical use: State of the art and 
perspectives of development. Silic. Ind. 1987, 9-10, 141-
146), DCPD slurries were prepared by combining a mixture 45 
of MCPM and �-TCP with a 1: 1 molar ratio at 1 gram total 
mass with 400 µL of 100 mM sodium citrate as a setting 
retardant to form the DCPD. Similar to CS, simvastatin was 
added to the 1 gram powder mixture prior to mixing with 
citrate at 10, 20 and 50 mg (1 wt%, 2 wt%, and 4.8 wt%, 50 
respectively). Mixing the components after the addition of 
sodium citrate-rather than prior-helps to slow the setting 
the previous vials were analyzed using UV spectroscopy. 
Release supernatant was mixed with an equal volume of 
reagent alcohol to dissolve any remaining simvastatin. After 
filtering at 0.45 µm, absorbance was measured at 240 nm. 
Compressive Mechanical Testing 
Bilayered and non-layered CS and DCPD samples were 
mechanically tested in compression using a BOSE ELF 
3300 system. After measuring dimensions, samples were 
loaded to failure at a rate of 0.5 N/s. From each sample's 
stress-strain curve, compressive elastic modulus [Eel and 
ultimate compressive stress [ au1,] were calculated. 
Destructive Degradation Testing 
A total of 30 unloaded non-layered DCPD samples were 
weighed and each sample was immersed in 4 mL of PBS. 
These samples were then allowed to dissolve at 37° C. on a
plate shaker. The supernatant was aspirated and the samples 
of the mixture. The DCPD slurry was packed firmly into a 
cylindrical Teflon mold of height 6.5 mm and diameter 4.75 
mm. Any trapped air was removed by tapping the mold on 55 
a hard surface as the slurry sets. The samples were then 
allowed to set in a fume hood at room temperature for 24 hrs. 
DCPD samples were then removed and stored in a dry 
environment at room temperature. DCPD samples had an 
average dry weight of 0.17±0.008 g. 
In order to prepare CS-shell-DCPD-core (CS/CP) 
samples, DCPD slurry was prepared. The slurry can also be 
mixed with 2 wt% simvastatin for a drug loaded core (CPs). 
The slurry was then packed into a cylindrical Teflon mold of 
height 10 mm and diameter 2.35 mm. The cement was then 65 
allowed to set in a fume hood at room temperature for 24 hrs. 
The samples were then removed and held in place at the 
60 were refilled with PBS at the end of every 4 days. At the end 
of every 8 days, 3 samples were collected, allowed to dry, 
and then weighed for percent change in mass. 
Microcomputed tomography (microCT) was used to 
evaluate the internal structure of samples during erosion. 
Samples were analyzed with a Scanco Medical µCT-40 
scanner. The specimens were evaluated with standard reso-
lution having 250 projections with 1024 samples each. 
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Additional parameters were set as follows: 92 µm incre­
ments, 01 angle, 70 kVp, 114 µA, 0.5 mm Al filter, and a 
voxel size of 12 µm. The resulting images were used to 
construct a three dimensional model with a built-in 'bone 
trabecular morphology' analytical tool at a lower threshold 5 
of 109. The scans and 3D image were then assessed quali­
tatively for obvious changes in the internal structure. 
Statistics 
Statistical analysis of the results was performed using 
either a two-tailed, unpaired t-test or one-way ANOVA. As 10 
appropriate, this was followed with a Tukey-Kramer mul­
tiple comparisons post hoc test. Any outliers were deter­
mined using Grubbs' test. Differences between groups were 
considered to be significant with p-value <0.05. 
Simvastatin Release Study 15 
Release of simvastatin from CS samples occurred at a 
much higher rate than DCPD samples, as expected from 
CS's faster dissolution rate. Within 28 days, CS samples 
were fully dissolved through surface erosion. FIG. 12 shows 
release profiles for CS and DCPD samples loaded each with 20 
1 wt % simvastatin (CS-1 and CP-1). Release rates were 
approximately 247 and 29 µg/day for CS-1 and CP-1, 
respectively. Increasing the amount of simvastatin added to 
DCPD resulted in a loading-dependent increase in release 
rate (i.e., 45 and 105 µg/day for 2 and 4.8 wt % simvastain 25 
loadings, respectively). 
FIG. 13 shows the release profiles for CP-1, CP-2 and 
CP-4.8 and indicates a less linear cumulative release at 
higher loadings. This is especially visible in CP-4.8 release 
profile where a large increase in release rate was seen 30 
between 32 and 76 days. During the first 32 days of release 
the rate for CP with 10, 20 and 4.8 wt % simvastatin was 22, 
29, 47 µg/day, respectively. From days 32 to 72, the release 
rate for the three samples increased to 37, 57, and 206 
µg/day, respectively. After the 72 days, the release rate for 35 
the three samples dropped to 26, 39, and 72 µg/day, respec­
tively. At the end of the 180 study of DCPD release, CP-1, 
CP-2, and CP-4.8 released a cumulative amount of 
1.21±0.33 mg, 1.82±0.30 mg, and 4.20±0.40 mg, respec­
tively,-all of which are significantly different from each 40 
other (p<0.05). Interestingly, CP-2 released a similar amount 
in the 180 days compared to the total release of CS 
(1.82±0.30 mg and 1.60±0.18 mg, respectively). 
At the end of the 120 day period, CS/CPs, CPs/CS, 
CPs/CSs, and CSs/CPs released a cumulative amount of 45 
229±57 µg, 401±125 µg, 679±210, 1169±197 µg, respec­
tively (FIG. 14). Compared to the cumulative release of 
CP-1, CP-2, and CP-4.8 samples at 120 days (862±288 µg, 
1388±255 µg, 3319±402 µg), CSs/CPs and CPs/CSs had a 
cumulative release comparable (p>0.05) to CP-2 and CP-1, 50 
respectively. Bilayered DCPD and CS samples released 
simvastatin at much slower rates compared to their non­
layered counterparts at almost all instances. CSs/CPs expe­
rienced the greatest average release rate of 7.5 µg/day. 
However, the release was not steady (R2=0.755); CSs/CPs 55 
had an average release of 32 µg/day in the first 20 days 
which then decreasing to 4.1 µg/day from then on. All other 
loadings experienced a much more steady release. CPs/CSs, 
CPs/CS, and CS/CPs released simvastatin at an average of 
26 
points (G> 1.672). One CP-4.8 sample also released signifi­
cantly higher on 28 data points (G> 1.672). Outliers in 
release were observed in other samples and categories 
however they did not occur as significantly frequent as the 
ones mentioned previously. No outliers were found in bilay­
ered release samples 
Compressive Mechanical Testing 
Mechanical testing showed DCPD to all have signifi­
cantly (p<0.05) greater ultimate compressive strength and 
compressive modulus than did CS (FIG. 15). There were no 
significant differences (p>0.05) in the two properties 
between DCPD blanks and the simvastatin loaded DCPD 
samples tested. The same quality was observed when com­
paring blank CS and simvastatin loaded CS. 
Additionally the strength and modulus of both bilayered 
samples were significantly lower (p<0.01) than those of 
DCPD blanks. Interestingly, the compressive mechanical 
properties of both bilayered samples were comparable 
(p>0.05) to that of CS blanks. There was also no significant 
difference found between the compressive mechanical prop­
erties of CS/CP bilayering compared to CP/CS bilayering 
(modulus-219±140 MPa and 220±68 MPa, respectively; 
strength---4.6±1.7 and 6.7±1.6, respectively). 
It is important to note that three outliers in modulus were 
found and removed from CS-1, CP-1 and CS/CP using 
Grubb's test for outliers. Data of one sample was missing for 
both CS-1 and CP-1, resulting in a sample size of 9. At a 
sample size of 10 and 9 with a confidence interval of 95%, 
G=2.176 and 2.11, respectively. It was found that a sample 
in CS-1 and CP-1 each had a significantly higher modulus 
(G>2.11) compared to its 8 other samples and was removed 
accordingly from the data as modulus sample size was 
adjusted to 8 for CS-1 and CP-1. One sample in CS/CP was 
found to be significantly higher as well for modulus and was 
removed according from the data as modulus sample size 
was adjusted to 9 for CS/CP. 
Destructive Degradation Study 
Over a period of 128 days, data was collected on the 
percent of remaining mass in samples every 8 days. The data 
showed a fairly constant decrease in mass (FIG. 15); how­
ever the change in percent remaining mass decreased gradu-
ally as the study progressed, suggesting a more logarithmic 
relationship. Percent loss in mass was fairly consistent 
between samples, indicated by the standard deviation bars. 
Between any two consecutive time points, there was no 
significant difference in mass loss (p>0.05), however at the 
end of the 120 days there accumulated a significant 
(p<0.001) mass loss of 36.8±2%. MicroCT scans also 
showed qualitatively that DCPD developed a porous internal 
structure as it eroded (FIG. 16). 
Simvastatin Release Study 
As loadings increased in non-layered DCPD samples, a 
larger release rate was seen between 32 and 76 days. The 
increase was much less obvious in lower loadings, however 
it can be clearly seen in 50 wt % loadings. It was observed 
that the average daily release suddenly increased in all 
DCPD samples between 32 and 76 days before decreasing to 
a rate slightly higher than the initial release rate during the 
first 32 days. The sudden increase can be due to the 
5 µg/day, 3.1 µg/day, and 1.92 µg/day, respectively. 60 formation of porous structures within the sample which 
increase surface area within the sample and proportionally 
increase simvastatin release. The subsequent drop in release 
can be attributed to the partial transformation of DCPD to 
It is important to note that after conducting Grubb's test 
for outliers, it was found that CP-1 and CP-4.8 each had one 
sample with more than 10 timepoints that were considered 
outliers; nevertheless, these outliers remain represented in 
FIG. 14. With a sample size of 5 and confidence interval of 65 
95%, G=l.672. A total of 45 data points were collected yet 
one CP-1 sample released significantly higher on 33 time-
the less soluble calcium deficient hydroxyapatite 
(CDHA) C-0.088 g/L vs. -o.0094 g/L at 25° C., respectively)
(Dorozhkin S V, Calcium Orthophosphates in Nature, Biol-
ogy and Medicine. Materials. 2009; 2(2):399-498) which 
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precipitated over time within and as a layer around the 
sample, thereby slowing the release of drug. 
In a similar in vitro study on the compositional changes 
during degradation in �-TCP and MCPM formulations of 
DCPD, there were slight CDHA conversions observed in a 5 
period of 14 days (Alge, D. L., Goebel, W. S., Chu, T-M. G. 
(2013) Effects of DCPD cement chemistry on degradation 
properties and cytocompatibility: comparison of MCPM/�­
TCP and MCPM/HA formulations. Biomedical Materials, 
8.2, 1-8). Acknowledging that conversions from DCPD to 10 
CDHA require crystal nucleation as the rate-limiting step 
(Bohner M et al 2003 Compositional changes of a di calcium 
phosphate dihydrate cement after implantation in sheep. 
Biomaterials 24 3463-74), it is likely that slight initial 
15 
CDHA conversions provided for nucleation sites for further 
CDHA precipitation. Based on observation and results, the 
precipitation of CDHA may have occurred both within 
DCPD as it dissolved to form its porous matrix and outside 
as a layer around the sample. As complex porous structures 20 
formed within the DCPD sample, it became increasingly 
more difficult for dissolved calcium and phosphate ions to 
leave the sample, leaving a saturated environment within the 
DCPD. This in turn would force the precipitation of the ions 
as the more stable and less soluble CDHA. The same effect 25 
28 
While CS dissolves much more rapidly than DCPD, its 
degradation can be retarded by surrounding it with the 
DCPD shell. In all CS core samples, CS dissolution lasted 
longer than the 28 days for CS non-layered samples and 
there was not as dramatic of an initial release as that of 
CSs/DCPDs samples. This quality is especially important 
for improved biocompatibility since the early dissolution of 
CS in CS/CP samples is associated with a significant drop in 
pH levels (McQuinn, M. (2014, September). Bilayered Cal­
cium Phosphate/Calcium Sulfate Bone Graft Substitutes. 
Poster presented at the 96'h Annual Scientific Sessions & 
Exhibition, Honolulu, Hi.). The release of simvastatin from 
DCPDs/CSs samples was much steadier than CSs/DCPDs. 
As expected, DCPDs/CS and CS/DCPDs formulations 
had a slower yet more linear release rate compared to other 
bilayered formulations. DCPDs shells release at a higher rate 
by occupying more volume compared to DCPDs cores. The 
formation of an empty core as DCPD-shell samples dissolve 
can also be beneficial for providing greater mechanical 
strength than a DCPD core while also allowing for bone 
growth to occur at the center of the shell. This can also help 
to promote the resorption of precipitated CDHA by increas­
ing surface area. 
It is important to note that the release of simvastatin is less 
predictable due to the effect of precipitation of CDHA as 
may have occurred outside the sample due to higher con- DCPD dissolves (Xie, J., Riley, C., Chittur, K. Effect of 
centrations of calcium and phosphate ions around the sample albumin on brushite transformation to hydroxyapatite. J.
due to dissolution at the surface and slight precipitation. This Biomed. Mater. Res. 2001, 57, 357-365; Ginebra, M. P.; 
effect can be seen in the mass loss of non-layered DCPD Canal, C.; Espanol, M.; Pastorino, D.; Montufar, E. B. 
samples which slows over a 120 day period despite increas- 30 Calcium phosphate cements as drug delivery materials. Adv. 
ing surface area due to increasing porosity. Thus, there is Drug Deliv. Rev. 2012, 64, 1090-1110). Additionally, there is 
evidence to suggest a conversion of DCPD into CDHA evidence to show that hydroxyapatite may form from CS 
which works to slow dissolution and drug release. formulations as well (Nilsson, M., Wang, J-S., Wielanek, L., 
The results from the release study suggest that higher Tanner, K. E., Lindgren, L. (2004). Biodegradation and 
loadings should be preferred over lower loadings in order to 35 biocompatibility of a calcium sulfate-hydroxyapatite bone 
have a higher average release rate, while lower loadings are substitute. The Journal of Bone & Joint Surgery (Br), 86-B, 
preferred over higher loadings in order to have a steadier 120-125). The formation of the apatite layer results in
release rate. Of the three loadings tested, CP-2 seems to be slowed release and was observed in this experiment. In two 
the ideal candidate for a higher release rate while maintain- of the CSs/DCPDs formulations, portions of the CSs outer 
ing its steadiness of release. Studies have shown beneficial 40 layers developed a hard shell that prevented them from fully 
effects of 1.2 mg topical application in human trials of dissolving the expected 28 days. This was also observed in 
simvastatin for mandibular defects (Pradeep AR, Priyanka DCPDs/CSs formulations where the dissolution of CSs was 
N, Kalra N, Naik S B, Singh S P, Martande S. Clinical halted by the precipitation of CDHA on both ends of the 
efficacy of subgingivally delivered 1.2-mg simvastatin in the cylinder. 
treatment of individuals with Class II furcation defects: a 45 Compressive Mechanical Testing 
randomized controlled clinical trial. J Periodontal. 2012; Blank DCPD samples tested in this study had an overall 
83:1472-9; Pradeep A R, Thorat M S. Clinical effect of mean compressive strength that was 219% higher than that 
subgingivally delivered simvastatin in the treatment of of the blank CS samples (14.27±2.46 MPa vs. 6.52±1.04 
patients with chronic periodontitis: a randomized clinical MPa). However, there were no significant changes (p>0.05) 
trial. J Periodontal. 2010; 81:214-22; Rao N S, Pradeep AR, 50 found in strength and modulus as loadings increased in CS 
Bajaj P, Kumari M, Naik S B. Simvastatin local drug and DCPD compared to their respective blanks. The quality 
delivery in smokers with chronic periodontitis: a random- for DCPD and CS to retain its mechanical properties at the 
ized controlled clinical trial. Aust Dent J. 2013; 58: 156-62). loadings tested in this experiment allows for more options in 
Knowing the performance of non-layered CS-1 and non- controlled drug release which is important for regions of 
layered CP-2, behavior of bilayered release of simvastatin 55 bone defect where healing is slower and requires increased 
with CS and DCPD layers can be predicted to an extent. Due drug loadings to compensate. 
to CS's rapid dissolution, CSs-shell layering was predicted It is important to note that DCPD samples have mechani-
to have a higher release rate in the first 28 days of its cal properties much greater than their CS counterparts and 
dissolution. This was supported by the release profile of this is seen in FIG. 14. Consequently, the addition of DCPD 
CSs/CPs in this experiment whose release in the first 20 days 60 to CS in a bilayered formation was expected to effectively 
was 780% greater than its release rate after that point. enhance the modulus and strength. However, properties 
Additionally, CS-shell samples would result in greater mass were similar to those of non-layered CS. Regardless, the 
loss since more surface area is exposed to outside condi- mechanical properties observed in this experiment were 
tions, leaving behind the slower degrading DCPD core. This comparable to or exceeded those of trabecular bone in the 
is beneficial for providing longer-lasting scaffolding for 65 mandible (96.2 MPa modulus; 3.9 MPa strength) (Misch C 
implantations while also allowing room for sufficient bone E, Qu Z, Bidez M W. Mechanical properties of trabecular 
growth as the outer CS layer dissolves. bone in the human mandible: Implications for dental implant 
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treatment planning and surgical placement. J Oral Maxi! 
Surg. 1999; 57:700-6; McQuinn, M. (2014, September). 
Bilayered Calcium Phosphate/Calcium Sulfate Bone Graft 
Substitutes. Poster presented at the 96'h Annual Scientific 
Sessions & Exhibition, Honolulu, Hi.). Furthermore, a 5 
redeeming quality in bilayered samples is that the inclusion 
ofDCPD allows for an adequate support structure in implan­
tation sites much longer than CS samples due to its slower 
dissolution. Additionally, as discussed in the previous sec­
tion, simvastatin loaded DCPD/CS layering allow for a 10 
steady and long term release. 
Destructive Degradation Study 
The DCPD biocements formulated in this experiment 
possess beneficial degradation properties for the purposes of 
promoting bone augmentation. DCPD forms porous struc- 15 
tures as it degrades through bulk degradation. These non­
erodible matrices form as DCPD degrades due to continuous 
dissolution and precipitation which result in less soluble 
CDHA crystals precipitating from the �-TCP, MCPM, and 
sodium citrate mixture (Bohner, M. pH variations of a 20 
solution after injecting brushite cements. Key Eng. Mater. 
2001, 192-195, 813-816; Alge, D. L., Goebel, W. S., Chu, 
T-M. G. (2013) Effects of DCPD cement chemistry on
degradation properties and cytocompatibility: comparison of
MCPM/�-TCP and MCPM/HA formulations. Biomedical 25 
Materials, 8.2, 1-8. http://stacks.iop.org/1748-605X/8/i=2/
a=025010). Contrastingly, CS undergoes surface erosion as
it dissolves. The structure of DCPD as it degrades can allow
for infiltration of mesenchymal cells while osteogenic activi­
ties are promoted by the local release of simvastatin. 30 
MicroCT scans showed slight surface imperfections in
DCPD samples even before degradation testing began.
These surface imperfections were found to be as wide as 100
µm in diameter which is sufficient for infiltration of osteo­
blasts (20-30 µm). A study done by Zerba et al (2005) 35 
confirmed the possibility of cell infiltration in porous �-TCP
samples through connected micropores as samples under­
went dissolution (Zerba, I. R., Brockers, A. L. J. J., Lange,
G., Burger, E. H. (2005) Localization of osteogenic and
osteoclastic cells in porous �-tricalcium phosphate particles 40 
used for human maxillary sinus floor elevation. Biomateri­
als, 26.12, 1445-1451).
Another property of the 13-TCP/MCPM formulation of 
DCPD is its ability to maintain pH as it degrades compared 
to other formulations such as MCPM and hydroxyapatite 45 
which significantly lower pH levels (Alge, D. L., Goebel, W. 
S., Chu, T-M. G. (2013) Effects ofDCPD cement chemistry 
on degradation properties and cytocompatibility: compari­
son of MCPM/�-TCP and MCPM/HA formulations. Bio­
medical Materials, 8.2, 1-8). This is an important factor to 50 
sustain biocompatibility of the samples. 
A problem with CS is its rapid dissolution which has been 
shown in animal trials and can have unfavorable outcomes 
(Thomas, M. V., Puleo, D. A., Calcium sulfate: A review. J. 
Long Term Eff. Med. Implants, 15(69):599-607, 2005, 55 
29(5):282-288, 2001; Nilsson, M., Wang, J-S., Wielanek, L., 
Tanner, K. E., Lindgren, L. (2004). Biodegradation and 
biocompatibility of a calcium sulfate-hydroxyapatite bone 
substitute. The Journal of Bone & Joint Surgery (Br), 86-B, 
120-125). This is presumably due to the rapid loss of CS 60 
mass and loss in mechanical properties which may not 
provide sufficient time or conditions for bone augmentation 
to occur. DCPD's much slower degradation rate may rem­
edy this issue. In this study, over a period of 120 days, 
DCPD samples maintained 63.18±2% of their initial mass 65 
while CS dissolved in 28 days. The much slower degrada­
tion rate in DCPD observed is also beneficial for maintain-
30 
ing a slow consistent release over a sustained period time as 
observed in the release study. 
For the purposes of effectively promoting bone growth 
while maintaining a strong support structure, simvastatin 
loaded CP/CS bilayered bioceramics may be an effective 
alternative to CS for procedures such as GBR. While CS 
proves to be a highly biocompatible and biodegradable 
material, its rapid dissolution is a quality that is largely 
undesired for larger areas of defect where bone healing 
would take longer than the 28 days which CS permits. The 
rapid dissolution of CS leads to the decline in its mechanical 
properties and can also generate gaps where bone growth 
'lags' behind (Nilsson, M., Wang, J-S., Wielanek, L., Tanner, 
K. E., Lindgren, L. (2004). Biodegradation and biocompat­
ibility of a calcium sulfate-hydroxyapatite bone substitute. 
The Journal of Bone & Joint Surgery (Br), 86-B, 120-125). 
Additionally, non-layered DCPD may not be ideal either due 
to its much slower degradation rate (> 180 days) which will 
permit little bone growth as the sample degrades. These 
issues can be addressed by combining the two ceramics 
using CP/CS bilayered bioceramics by providing a longer 
lasting support structure (DCPD) while also permitting 
sufficient bone growth to occur within the core as the faster 
degrading CS is dissolved. After bone ingrowth has occurred 
within the core of the DCPD shell, mechanical properties 
can expect to see a boost due to the presence of both bone 
and DCPD. Additionally, cell infiltration and resorption can 
occur on both sides of the DCPD shell, thereby allowing for 
better integration of bone and effectively reducing the deg­
radation time ofDCPD. Additionally, the osteogenic activity 
will be enhanced by the steady and predictable release of 
simvastatin from the sample, all without compromising the 
initial mechanical strength of the commonly used CS. 
CS and DCPD are both proven alternatives to conven­
tional bone grafts. DCPD possesses advantages such as 
stronger mechanical strength, prolonged release, and inter­
nal conditions which promote bone growth. Preferred load­
ing amounts in DCPD were determined to be 2 wt %, and 
increased loadings up to 4.8 wt % did not affect the mechani­
cal strength of the material. Additionally, bilayered CS and 
DCPD samples were tested where it was discovered that 
CSs/CPs samples released more simvastatin at any period of 
its degradation compared with any other layering option, 
however CSs/CPs had a much steadier release rate and 
higher mechanical strength which is equivalent to that of CS. 
Bilayered CS and DCPD samples may allow for more 
options for treatment of bone defects rather than using solely 
CS or DCPD. Ultimately, the use of one bioceramic over the 
other will depend on the desired compressive strength, 
degradation, and drug release when confronted with differ­
ent sites for bone augmentation. However, CPs/CSs formu­
lations seem to be a more interesting candidate for future in 
vivo testing and applications. 
The foregoing descriptions of various embodiments pro­
vide illustration of the inventive concepts. The descriptions 
are not intended to be exhaustive or to limit the disclosed 
invention to the precise form disclosed. Modifications or 
variations are also possible in light of the above teachings. 
The embodiments described above were chosen to provide 
the best application to thereby enable one of ordinary skill 
in the art to utilize the inventions in various embodiments 
and with various modifications as are suited to the particular 
use contemplated. All such modifications and variations are 
within the scope of the invention. All publications, patents 
and patent applications referenced herein are to be each 
individually considered to be incorporated by reference in 
their entirety. 
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We claim: 
1. A bilayered bone graft composite for bone augmenta­
tion comprising an outer shell layer comprised of a first 
bioceramic and an inner core layer comprised of a second 
bioceramic, wherein the first and second bioceramics are 
different such that one layer degrades in situ within a subject 
at a rate faster than the other layer to allow for cell 
infiltration in situ with the slower degrading layer preformed 
to mechanically support the bilayered bone graft composite 
and surrounding tissue in situ and further wherein the inner 
core layer is encased by the outer core layer. 
2. The bilayered composite of claim 1, wherein the outer
shell layer degrades faster than the inner core layer. 
3. The bilayered composite of claim 1, wherein the inner
core layer degrades faster than the outer shell layer. 
4. The bilayered composite of claim 1, wherein one layer 
c?mp�ises a material selected from the group consisting of
d1calcmm phosphate dihydrate (DCPD), hydroxyapatite, 
calcium-deficient hydroxyapatite, carbonate-substituted 
hydroxyapatite, and calcium polyphosphate. 
5. The bilayered composite of claim 4, wherein the other
layer comprises a material selected from the group consist­
ing of calcium sulfate (CS), �-tricalcium phosphate, amor­
phous calcium phosphate, monetite, and tetracalcium phos­
phate. 
6. The bilayered composite of claim 1, wherein one layer
comprises calcium sulfate and the other layer comprises 
calcium phosphate. 
7. The bilayered composite of claim 6, wherein the
calcium phosphate is dicalcium phosphate dihydrate. 
8. The bilayered composite of claim 1, wherein at least
one layer further comprises a pharmaceutical agent selected 
32 
from the group consisting of: simvastatin, lovastatin, rosu­
vastatin, bone morphogenetic proteins, human parathyroid 
hormone fragment 1-34, metronidazole, doxycycline, van­
comycin, gentamycin, ciprofloxacin, ketoprofen, celecoxib, 
diclofenac, meloxicam or combinations thereof. 
9. The bilayered composite of claim 8, wherein both
layers further comprise a pharmaceutical agent. 
10. The bilayered composite of claim 8, wherein the
pharmaceutical agent is preloaded in a degradable matrix or 
10 a hydrogel. 
11. The bilayered composite of claim 1, wherein the
subject is an animal. 
12. The bilayered composite of claim 1, wherein the
subject is a human. 
15 13. The bilayered composite of claim 1, wherein the outer
layer further comprises polymer particles. 
14. The bilayered composite of claim 1, wherein the inner
layer further comprises polymer particles. 
15. The bilayered composite of claim 1, wherein the inner
20 layer and the outer layer form concentric cylinders. 
16. A method of providing tissue support to a subject in
need thereof, comprising administering the bilayered com­
posite of claim 1 to tissue of the subject.
17. The method of claim 16, further comprising preload-
25 ing one layer with a pharmaceutical agent. 
18. The method of claim 17, wherein the pharmaceutical
agent is in a degradable matrix or hydrogel within the layer.
19. The method of claim 16, wherein both layers further
comprise preloading with a pharmaceutical agent. 
30 20. The method of claim 16, wherein the tissue is osseous
tissue.
* * * * *
